



# Program

# 2022 PNS Annual Meeting

14-17 May Miami, Florida

#### **CONNECT WITH PNS**





Tag your meeting posts with **#PNS2022** 

www.pnsociety.com

# TABLE OF CONTENTS


Welcome3	MONDAY, 16 MAY
Leadership and Program Organizers 4	Alnylam Sponsored Symposium
Membership Information	Grifols Sponsored Symposium
About the Society8	Anita Harding Plenary Lecture
InterContinental Miami Hotel Floor Plans 9	Platform Session III
Program At A Glance	Oral Poster Session III
General Information	Jack Griffin Plenary Lecture
Acknowledgments	Platform Session IV
Industry-Sponsored Symposia	Oral Poster Session IV
In-Conjunction-With Meetings19	PNS Annual General Meeting
PROGRAM	Guided Poster Hall Tours (Concurrent Sessions)  COVID/Vaccine Neuropathy
SATURDAY, 14 MAY	Stem Cells
	Special Interest Group (SIG) Concurrent Sessions
Education Course	Charcot-Marie-Tooth & Related
(pre-registration required)	Neuropathies Consortium (CMTR)
Education Course Keynote Symposium	International Diabetes Neuropathy42
Junior & Welcome Reception24	Consortium (IDNC)
(first hour reserved for Junior Members and	Toxic Neuropathy Consortium (TNC)
New Members only)	Pfizer Sponsored Symposium
New Members Only)	Takeda Sponsored Symposium
SUNDAY, 15 MAY	
Peter J. Dyck Plenary Lecture25	TUESDAY
Platform Session I	PK Thomas Plenary Lecture
Oral Poster Session I	Platform Session V
Richard & Mary Bunge Plenary Lecture 26	Oral Poster Session V
Platform Session II	Jonathan Pembroke Plenary Lecture
Oral Poster Session II	Platform Session VI49
Poster Session I	Oral Poster Session VI
Guided Poster Hall Tours (Concurrent Sessions)	Poster Session II
Antibodies & Immunity	Guided Poster Hall Tours (Concurrent Sessions)
Diagnostics & Imaging in Neuropathies 28	Fluid Biomarkers
Special Interest Group (SIG) Concurrent Sessions	Trials & Therapies
Inflammatory Neuropathy Consortium (INC)28	Basic Science Highlights51
Neuropathic Pain Consortium (NPC)31	Richard A.C. Hughes Symposium
CSL Behring Sponsored Symposium	Clinical Highlights
IONIS Sponsored Symposium	Arthur K. Asbury/Presidential
	Plenary Lecture
	Awards Ceremony
	Closing Reception
	Exhibitor Map57
	Exhibitor Directory



### **WELCOME**

On behalf of the Peripheral Nerve Society, please let me welcome you to the 2022 Annual Meeting in Miami.

The PNS Annual Meeting continues to be the premier meeting for learning about advances in peripheral neuropathy and peripheral nerve biology. The Program Committee has organized a spectacular meeting with the traditional mixture of carefully selected plenary lectures, oral platforms, and oral posters, as well as symposia that were organized by the special interest groups — Charcot-Marie-Tooth and Related Neuropathies Consortium (CMTR), the Inflammatory Neuropathy Consortium (INC), the International Diabetes Neuropathy Consortium (IDNC), Neuropathic Pain Consortium (NPC), and the Toxic Neuropathy Consortium (TNC). We are excited to bring back the innovative clinical highlights and hold the basic science highlights sessions on Tuesday, 17 May.



We are excited to be meeting again in person this year finally. We're bringing back the guided poster hall tours introduced in a virtual format in 2021 but will now be in person this year.

We also invite our Junior Members to participate in the Education Course and Career Development Lunch on Saturday, 14 May. New this year, the first hour of our Junior & Welcome Reception will be dedicated to Junior Members only (all others are invited to join after the first hour concludes).

I encourage you to attend the PNS Annual General Meeting on Monday, 15 May at 12.00 EDT (US and Canada). Your input is valuable as we discuss the current business and the future of the PNS.

Finally, don't miss our exciting PNS Closing Reception to be held on the 5th floor pool deck of the hotel on Tuesday evening.

I want to personally thank the Scientific Program Committee, Local Organizing Committee, Junior Committee, PNS Board, staff, our sponsors, and everyone who has generously donated their time and efforts to put together the outstanding program of the meeting. I hope you will enjoy the 2022 PNS Annual Meeting and look forward to connecting with you there.

Richard Lewis, MD

President, Peripheral Nerve Society



# PNS LEADERSHIP AND PROGRAM ORGANIZERS

#### PNS BOARD OF DIRECTORS

#### **OFFICERS**

Richard Lewis, MD, President, Cedars-Sinai, Los Angeles, CA, USA
Laura Feltri, MD, President-Elect, SUNY at Buffalo, Buffalo, NY, USA
Michael Polydefkis, MD, MHS, Secretary/Treasurer, Johns Hopkins Medicine, Baltimore, MD, USA
Pieter van Doorn, MD, PhD, Immediate Past President, Erasmus MC University Medical Center, Rotterdam, Netherlands

#### **BOARD MEMBERS**

Ahmet Hoke, MD, PhD, Johns Hopkins University, Baltimore, MD, USA
Stefano C. Previtali, MD, PhD, IRCCS San Raffaele Scientific Institute, Milan, Italy
Claudia Sommer, MD, Department of Neurology, University Hospital Würzburg, Würzburg, Germany
Charlotte Sumner, MD, Johns Hopkins Medicine, Baltimore, MD, USA
Peter Van den Bergh, MD, PhD, FEAN, FAAN, University Hospital St-Luc, Brussels, Belgium
Hugh Willison, MD, PhD, University of Glasgow, Glasgow, United Kingdom

Charcot-Marie-Tooth and Related Neuropathies Consortium (CMTR) Representative Stephan Zuchner, MD, PhD, University of Miami, Miami, FL, USA

Inflammatory Neuropathy Consortium (INC) Representative Chiara Briani, MD, University of Padova, Padova, Italy

International Diabetes Neuropathy Consortium (IDNC) Representative

James Russell, MD, MS, CAMC Institute for Academic Medicine, Charleston, WV, USA

Neuropathic Pain Consortium (NPC) Representative

Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

Toxic Neuropathy Consortium Representative
Guido Cavaletti, MD, University of Milano-Bicocca, Monza, Italy

#### JPNS Editor in Chief

**Giuseppe Lauria, MD,** IRCCS FONDAZIONE ISTITUTO NEUROLOGICO CARLO BESTA & UNIVERSITY OF MILAN, Milano, Italy

#### **Board Advisor**

David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA

Junior Committee Representative

Kathryn Moss, PhD, Johns Hopkins University, Baltimore, MD, USA



# PNS LEADERSHIP AND PROGRAM ORGANIZERS

#### SCIENTIFIC PROGRAM COMMITTEE

#### **Scientific Program Committee Co-Chairs**

Wendy Campana, PhD, UC San Diego/San Diego VA Health System, San Diego, CA, USA Simon Rinaldi, PhD, University of Oxford, Oxford, United Kingdom

#### **Clinical Highlights Chairs**

David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA Mary Reilly, MD, FRCP, FRCPI, FMedSci, University College London, London, United Kingdom

#### **Basic Science Highlights Chairs**

Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA

Ruth Huizinga, PhD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

#### **Prize Committee Chairs**

Andrea Cortese, MD, PhD, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

#### **CMTR** Representative

Stephan Zuchner, MD, PhD, University of Miami, Miami, FL, USA

#### **IDNC** Representative

James Russell, MD, MS, CAMC Institute for Academic Medicine, Charleston, WV, USA

#### **INC** Representative

Chiara Briani, MD, University of Padova, Padova, Italy

#### **TNC Representative**

Guido Cavaletti, MD, University of Milano-Bicocca, Monza, Italy

#### **NPC Representative**

Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

#### **EAN Representative**

Davide Pareyson, MD, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy

#### **Members**

Paola Alberti, MD, PhD, University of Milano-Bicocca, Monza, Italy Haesun Kim, PhD, Rutgers University Newark, NJ, USA

Kleopas Kleopa, MD, FAAN, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus Jun Li, MD, PhD, Wayne State University, Detroit, MI, USA

Kathryn Moss, PhD, Johns Hopkins University, Baltimore, MD, USA

Lucia Notterpek, PhD, University of Nevada, Reno School of Medicine, Reno, NV, USA

Luis Querol, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Maureen Su, MD, UCLA, Los Angeles, CA, USA

Charlotte Sumner, MD, Johns Hopkins Medicine, Baltimore, MD, USA



# PNS LEADERSHIP AND PROGRAM ORGANIZERS

#### JUNIOR COMMITTEE

Kathryn Moss, PhD, Chair, Johns Hopkins University, Baltimore, MD, USA
Paola Alberti, MD, PhD, Vice-Chair, University of Milano-Bicocca, Monza, Italy
Mirlinda Ademi, MD, University of Cambridge, Cambridge, United Kingdom
Janev Fehmi, MD, NDCN University of Oxford, Oxford, United Kingdom
Tiffany Li, PhD Candidate, The University of Sydney, Sydney, Australia
Christian Moritz, PhD, Intitut NeuroMyoGène, University of Lyon / Saint-Étienne, Lyon, France
Marcus Pinto, MD, MS, Mayo Clinic, Rochester, MN, USA
Leena Shingavi, MD, PhD, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India
Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA
Luuk Wieske, MD, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands

#### PRIZE COMMITTEE

Andrea Cortese, MD, PhD, Co-Chair, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom Daniela Menichella, MD, PhD, Co-Chair, Northwestern University, Chicago, IL, USA

Christopher Gibbons, MD, MMSc, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Luis Querol, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Sandra Rieger, PhD, University of Miami, Miami, FL, USA

Charlotte Sumner, MD, Johns Hopkins Medicine, Baltimore, MD, USA

Douglas Wright, PhD, University of Kansas Medical Center, Kansas City, KS, USA



# **MEMBERSHIP INFORMATION**



We invite you to join the Peripheral Nerve Society (PNS). The Society is dedicated to improving the lives of people with peripheral neuropathies throughout the world. Becoming a member of PNS means collaborating with prominent global professionals to develop and provide the best treatments for people with peripheral nerve diseases and setting standards of care within the field. PNS provides annual meetings, in-person and online teaching courses, guidelines, and other resources to aid in the education of members.

Membership in the Peripheral Nerve Society is open to any professional interested in disorders of the peripheral nervous system. Our membership includes clinicians, academicians, basic and clinical scientists, members of industry, and representatives from neuropathy organizations.

#### PNS Membership Features Include:

- Online subscription to Journal of the Peripheral Nervous System (JPNS)
- On-Demand Education Center Access
- Online Communities Forum Access
- PNS Membership Directory Access
- Member Only Job Postings
- Special Interest Group Memberships
- Volunteer & Leadership Opportunities
- Discounted Meeting & Event Registration Rates

Visit <u>www.PNSociety.com</u> for information on membership dues, categories, rates, and to join today. Please note: the PNS extends a membership discount to those joining the PNS from low-income and middle-income economies (GNI per capita of \$12,535 or less).



# ABOUT THE SOCIETY

The Peripheral Nerve Society (PNS) was founded in 1994 by two groups of academic investigators, the Peripheral Nerve Study Group and the Peripheral Neuropathy Association of America, interested in the basic biology and function of the peripheral nervous system and its application to the clinic. Their invite-only, biennial meetings involved 80-125 attendees in cloistered settings organized by shoestring and local initiatives. From this, we have grown remarkably. We now have an annual meeting of over 1000 people, including meetings within the meeting for the special interest groups in inflammatory, diabetic, toxic, pain, and hereditary neuropathy. With this substantial growth and the success of JPNS, the Journal of the Peripheral Nervous System, the Society continues to flourish. Please click here to view past meetings of the PNS.

We invite you to get involved in the PNS by volunteering for a project aligned with your interests. Have specific ideas? Please send them to the Executive Office at <a href="mailto:info@PNSociety.com">info@PNSociety.com</a> or a Board Member.

### PNS EXECUTIVE OFFICE STAFF



Allison Kindseth, CMP
Executive Director



Jacquie Durant
Meetings & Strategic
Partnership Manager



Glenn Stanley
Education &
Communications Manager


## **CONTACT US**

1935 County Road B2 W, Ste 165
Roseville, MN 55113 USA
+1-952-545-6284
info@PNSociety.com
www.PNSociety.com




# INTERCONTINENTAL MIAMI HOTEL FLOOR PLANS

#### **LOBBY LEVEL 1**



#### **MEZZANINE LEVEL 2**





# PROGRAM AT A GLANCE

	SATURDAY 14 MAY 2022		SUNDAY 15 MAY 2022	
8.00-10.20	Coffee & Registration MEZZANINE (2ND FLOOR)	6.30-7.45	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)	
8.00-12.00	Inherited Neuropathy Meeting (Closed Meeting) SANDRINGHAM/WINDSOR (2ND FLOOR)	6.30-7.45	Poster Viewing BISCAYNE BALLROOM (2ND FLOOR)	
9.00-10.15	IGOS Meeting (Closed Meeting) RAPHAEL/MICHELANGELO (2ND FLOOR)	7.45-8.00	Presidential Welcome Richard Lewis, MD GRAND BALLROOM (2ND FLOOR)	
10.20-18.30	Education Course (All Are Welcome) VERSAILLES (2ND FLOOR)	8.00-8.30	Peter J Dyck Lecture: Diabetes GRAND BALLROOM (2ND FLOOR)	
10.20	<b>Microphysiological Models of Peripheral Nerve</b> Michael J. Moore, PhD		Diabetic Neuropathy: Light at the End of the Funnel? Nigel Calcutt, PhD	
11.00	Basics of Nerve Conduction/ Electromyography: From the Clinic to the Lab Paola Alberti, MD, PhD; David Cornblath, MD	8.30-9.30 9.30-10.00	Platform Session I GRAND BALLROOM (2ND FLOOR) Oral Poster Session I	
11 40	Diagnosing and Misdiagnosing CIDP:	7.50-10.00	GRAND BALLROOM (2ND FLOOR)	
11.40	Pitfalls and Red Flags	10.00-10.30	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)	
10.00.10.50	Jeffrey Allen, MD	10.30-11.00	Richard and Mary Bunge Lecture:	
	Lunch GRAND BALLROOM FOYER (2ND FLOOR)		Biology of Nerve GRAND BALLROOM (2ND FLOOR) Molecular Mechanisms Controlling PNS Myelin	
	IMAGiNe Study Consortium Q&A Session (Closed Meeting) RAPHAEL/MICHELANGELO		Formation and Maintenance Carla Taveggia, PhD	
12.30-13:40	Career Development Lunch (Pre-Registration Required) TRIANON (2ND FLOOR)	11.00-11.45	Platform Session II GRAND BALLROOM (2ND FLOOR)	
13.40-15.10	CMTR Workgroup Meeting (All are welcome) SANDRINGHAM/WINDSOR (2ND FLOOR)	11.45-12.00	Oral Poster Session II GRAND BALLROOM (2ND FLOOR)	
	Education Course Cont. VERSAILLES (2ND FLOOR)	12.00-14.00	Lunch & Exhibits MEZZANINE (2ND FLOOR)	
13.50	Mechanisms and Consequences of	12.00-14.00	$\textbf{Poster Session I} \ \ \texttt{BISCAYNE BALLROOM (2ND FLOOR)}$	
	<b>De- vs. Dysmelination</b> Jun Li, MD, PhD	13.00-13.30	Guided Poster Hall Tour: Antibodies & Immunity VERSAILLES (2ND FLOOR)	
14.30	<b>Hallmarks of Non-CMT Inherited Neuropathies</b> Vera Fridman, MD	13.00-13.30	Guided Poster Hall Tour: Diagnostics & Imaging in Neuropathies TRIANON (2ND FLOOR)	
15.10	Neuroinflammation: Mechanisms Leading to Axonal Damage and Neuropathic Pain in Chemotherapy-induced Peripheral Neurotoxicity	14.00-19.00	Special Interest Group (SIG) Concurrent Sessions	
	Guido Cavaletti, MD	INFLAMMATORY NEUROPATHY CONSORTIUM (INC) VERSAILLES (2ND FLOOR)		
15.50	Pure Neural Leprosy		(2ND FLOOR) The Role of Complement in Immune	
1/ 20 17 00	Wilson Marques Junior, MD, PhD	14.00	Mediated Neuropathies	
	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)  Keynote Symposium: Nodes of Ranvier:		Peter J Spaeth, PhD	
17.00-18.30	From Assembly to Nodo-Paranodopathies (three-part talk) VERSAILLES (2ND FLOOR)	14.45	Biomarkers of Disease Activity in Immune-Mediated Neuropathies Jeffrey Allen , MD	
17.00	Nodes, Paranodes and Juxtaparanodes:	15.30	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)	
	Normal Anatomy and Physiology Kleopas Kleopa, MD, FAAN	16.00	Oral Poster Presentations	
17.25	Immunology of the Node of Ranvier	17.00	INC Project Updates	
47.50	Luis Querol, MD, PhD	17.30	Autoimmune Autonomic Neuropathies Valeria Iodice, MD, PhD	
17.50	Nodo-Paranodopathies: Clinical Phenotypes and Treatment Antonino Uncini, MD	18.15	Autoantibodies Associated with Paraneoplastic Neuropathies:	
18.15	General Discussion (Q&A)		Growing Spectrum and Relevance	
19.00-22.00	Junior and Welcome Reception PEREZ ART MUSEUM MIAMI (PAMM)		Divyanshu Dubey, MD	



First hour is reserved for Junior Members and New Members only. Buses will depart from the InterContinental Miami Hotel lobby at 18.45

# PROGRAM AT A GLANCE

	SUNDAY 15 MAY 2022 (cont.)	12.00-12.30	PNS Annual General Meeting (all are welcome) GRAND BALLROOM (2ND FLOOR)
	nic Pain Consortium (NPC) TRIANON (2ND FLOOR)	12.30-14.00	Lunch & Exhibits MEZZANINE (2ND FLOOR)
14.00	Physiologic and Transcriptomic Findings in Human Dorsal Root Ganglia Patrick Dougherty, PhD	13.00-13.30	Guided Poster Hall Tour: COVID/Vaccine Neuropathy VERSAILLES (2ND FLOOR)
14.30	Platform Presentations	13.00-13.30	Guided Poster Hall Tour: Stem Cells TRIANON (2ND FLOOR)
15.00	Cannabinoids, Cannabis, and Cannabis-Based Medicines for Neuropathic Pain Management Andrew Rice, MD, FRCP, FRCA	14.00-19.00	Special Interest Group (SIG) Concurrent Sessions
	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)  Skin in the Game: Keratinocytes Communicate		T-MARIE-TOOTH & RELATED NEUROPATHIES TIUM (CMTR) VERSAILLES (2ND FLOOR)
10.00	with Sensory Neurons to Convey Pain Cheryl Stucky, PhD		An Update on Treating ATTR Amyloidosis Isabel Conceição, MD
16.30	Oral Poster Presentations	14.30	Platform Presentations
17.00	<b>Skin Biopsy in the Clinic</b> Claudia Sommer, MD	15.00	The Genetics of Pain-Related Neuropathies Ingo Kurth, MD
17.30	Platform Presentations	15.30	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)
18.00	Sensory Neurons Modulate Skin Inflammation		Platform Presentations
10 20	Dan Kaplan, MD, PhD  Panel Discussion with all Speakers	16.30	Mechanistic Understanding and Therapeutic
19.00-19.15	Break MEZZANINE (2ND FLOOR)		Discovery for Peripheral Neuropathy using Drosophila Models
19.15-20.15	Sponsored Symposia	17.00	Grace Zhai, PhD  Platform Presentations
	CSL Behring Symposium TRIANON (2ND FLOOR)		Outcome Measures and Niomarkers in CMT
	IONIS Symposium VERSAILLES (2ND FLOOR)	17.30	for Successful Trial Readiness David Herrmann, MBBCh
	MONDAY 16 MAY 2022	18.00	Platform Presentations
6.45-8.00	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)		Late Breaking Abstracts
6.45-7.45	Sponsored Symposia		<u> </u>
	Alnylam Symposium CHOPIN (2ND FLOOR) Grifols Symposium GRAND BALLROOM (2ND FLOOR)		FIONAL DIABETES NEUROPATHY FIUM (IDNC) CHOPIN (2ND FLOOR)
8.00-8.30	Anita Harding Lecture: Female Pioneer	14.00	Welcome James Russell, MD
	GRAND BALLROOM (2ND FLOOR)  The Role of Blood Neural Barriers in  Motor Nerve Degeneration  Charlotte Sumner, MD		Programmed Axon Death and Human Disease Pathogenic and Therapeutic Implications in Diabetic Neuropathy
8.30-9.30	Platform Session III GRAND BALLROOM (2ND FLOOR)	1/ 50	Michael Coleman, PhD Platform Presentations
8.30-9.30	Patient Advocacy Group (PAG) Meeting (Closed Meeting) BALMORAL (2ND FLOOR)		Coffee Break & Exhibits MEZZANINE (2ND FLOOR)
9.30-10.00	Oral Poster Presentations III GRAND BALLROOM (2ND FLOOR)		Emerging Biomarkers in Diabetic Neuropathy Vera Fridman, MD
10.00-10.30	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)	16.45	Neuroimmune Regulation of Remission and
	IGOS Biobank Meeting (Open Meeting) BALMORAL (2ND FLOOR)		Relapse of Neuropathic Pain Geoffroy Laumet, PhD
10.30-11.00	Jack Griffin Lecture: Regeneration GRAND BALLROOM (2ND FLOOR) The Schwann Cell-Associated Secretory		Inflammation as a Therapeutic Target for Diabetic Peripheral Neuropathy Rodica Pop-Busui, MD, PhD
	Phenotype as a Therapeutic Target		Oral Poster Presentations
	for Nerve Repair Felipe A. Court, PhD	18.40	The Unmet Need for Disease Modification in Diabetic Peripheral Neuropathy.
11.00-11.45	Platform Session IV GRAND BALLROOM (2ND FLOOR)		<b>First Steps: The Taxonomy Project</b> Roy Freeman, MD
11.45-12.00	Oral Poster Session IV GRAND BALLROOM (2ND FLOOR)	18.55	Closing Remarks James Russell, MD



# PROGRAM AT A GLANCE

	MONDAY 16 MAY 2022 (cont.)	10 30-11 00	Jonathan Pembroke Lecture: Cell Biology	
		10.00 11.00	GRAND BALLROOM (2ND FLOOR)	
TRIANON (2	•		Transduction of Light Touch and Mechanical Pain by Sensory Schwann Cells	
14.00	Emerging Mechanisms of Nerve Damage	44.00.44.45	Patrik Ernfors, PhD	
	in CIPN Nathan Staff, MD, PhD	11.00-11.45	Platform Session VI GRAND BALLROOM (2ND FLOOR)	
14.30	Different Approaches to CIPN Assessment: Serum Biomarkers	11.45-12.00	Oral Poster Session VI GRAND BALLROOM (2ND FLOOR)	
	Paola Alberti, MD	12.00-14.00	Lunch & Exhibits MEZZANINE (2ND FLOOR)	
	Apps and Wearables for Remote CIPN Monitoring	12.00-14.00	Poster Session II BISCAYNE BALLROOM (2ND FLOOR)	
15.10	Daniel Hertz, PharmD, PhD	13.00-13.30	Guided Poster Hall Tour: Fluid Biomarkers VERSAILLES (2ND FLOOR)	
	General Discussion Coffee Break & Exhibits MEZZANINE (2ND FLOOR)	13.00-13.30	Guided Poster Hall Tour: Trials & Therapies TRIANON (2ND FLOOR)	
16.00	Update on TNC Activities	14.00-16.00	Basic Science Highlights VERSAILLES (2ND FLOOR)	
16.30	Guido Cavaletti, MD  Platform Presentations		Richard A.C. Hughes Symposium: Clinical Highlights TRIANON (2ND FLOOR)	
15.30-16.00	JPNS Editorial Board Meeting	16.00-16.30	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)	
19.00-19.15	(Closed Meeting) BALMORAL (2ND FLOOR) Break MEZZANINE (2ND FLOOR)	16.00-16.30	Prize Committee Meeting (Closed Meeting) GROVE (1ST FLOOR)	
19.15-20.15	Sponsored Symposia	16.00-16.30	PNS Annual Partner Roundtable Meeting (Closed Meeting) BALMORAL (2ND FLOOR)	
	Pfizer Symposium TRIANON	16.30-17.00	Arthur K. Asbury/Presidential Lecture:	
20.45.24.45	Takeda Symposium VERSAILLES		GBS/CIDP/Inflammatory Neuropathy	
20.15-21.15	IDNC Board Meeting (Closed Meeting) BALMORAL (2ND FLOOR)		GRAND BALLROOM (2ND FLOOR) Improve the Lives of People with Peripheral Neuropathies	
	TUESDAY 17 MAY 2022		Pieter van Doorn, MD, PhD	
6.45-8.00	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)		Awards Ceremony GRAND BALLROOM (2ND FLOOR)	
6.45-8.00	Poster Viewing BISCAYNE BALLROOM (2ND FLOOR)	17.30-18.30	NPC Board Meeting (Closed Meeting) BALMORAL (2ND FLOOR)	
8.00-8.30	PK Thomas Lecture: Inherited Neuropathies GRAND BALLROOM (2ND FLOOR) Gene Therapies for Inherited Demyelinating Neuropathies Kleopas Kleopa, MD, FAAN	19.00-22.00	Closing Reception INTERCONTINENTAL MIAMI SKYLAWN (LEVEL P, 5TH FLOOR POOL DECK)	
8.30-9.30	Platform Session V GRAND BALLROOM (2ND FLOOR)		WEDNESDAY 18 MAY 2022	
9.30-10.00	Oral Poster Session V GRAND BALLROOM (2ND FLOOR)	7.30-8.30	CMTR Board Meeting (Closed Meeting) ESCORIAL (2ND FLOOR)	
10.00-10.30	Coffee Break & Exhibits MEZZANINE (2ND FLOOR)	7.30-8.30	INC Board Meeting (Closed Meeting)	
10.00-10.30	TNC Board Meeting (Closed Meeting) BALMORAL (2ND FLOOR)	9.00-12.00	RAPHAEL/MICHAELANGELO (2ND FLOOR)  PNS Board Meeting (Closed Meeting)  RAPHAEL/MICHAELANGELO (2ND FLOOR)	



# **GENERAL INFORMATION**

#### REGISTRATION/HELP DESK HOURS (MEZZANINE / SECOND FLOOR)

Saturday, 14 May 8.00-19.00 Sunday, 15 May 6.30-19.00 Monday, 16 May 6.30-19.00 Tuesday, 17 May 6.45-17.30

#### SPEAKER READY ROOM (OXFORD / SECOND FLOOR)

All speakers must upload their presentations here at least 90 minutes before the session starts.

Saturday, 14 May 8.00-19.00 Sunday, 15 May 6.00-20.30 Monday, 16 May 6.00-20.30 Tuesday, 17 May 6.30-17.30

#### CERTIFICATE OF ATTENDANCE

Your certificate of attendance will be emailed to you after the meeting upon completion of the meeting evaluation.

#### IN PERSON REGISTRATION FEES

Registration fees include:

- Saturday Education Course
- Three full days of regular programming with special interest group afternoon sessions
- Two exciting receptions
- Access to exhibit hall and directory
- Access to on-demand content and E-Poster Hall through 31 December 2022
- A chance to network with friends, old and new
- Breakfast, Lunch, and Coffee breaks

#### NAME BADGE

All participants (including guests) are required to wear their name badge at all PNS sanctioned events.



<sup>\*</sup>Note: Speaker designations are listed in the program, as submitted

# **GENERAL INFORMATION**

#### **FACE MASK POLICY**

To protect the safety of our community, all attendees (including guests) are required to wear a face mask at all PNS sanctioned events. Those participating in a panel discussion or speaking from the podium will be exempt. Attendees will also not be required to wear a mask while actively eating or drinking.

#### LIABILITY & INSURANCE

The organizers accept no responsibility for any injury or damage involving persons and property during the 2022 PNS Meeting.

#### MOBILE APP INFORMATION

Navigate the event like a pro with the PNS 2022 Annual Meeting mobile app, powered by Core-apps.com.

#### With the PNS 2022 Annual Meeting app, you can:

- Stay organized with up-to-the-minute speaker, exhibitor and event information
- Receive critical real-time communications from PNS
- Build a personalized schedule and bookmark exhibitors
- Take notes
- Stay in-the-know and join in on social media with #PNS2022
- Share your event photos and experience with the Photo Gallery
- And much, much more!

#### **DOWNLOADING THE APP IS EASY!**

While on your smartphone, visit <a href="https://bit.ly/3Lv4cUd">https://bit.ly/3Lv4cUd</a> to download the mobile app to your device.

Access the Complimentary
WiFi at the InterContinental Miami
(Available in PNS Meeting Space)

**Network: ICConnect** 

Password: Miami2022 (case sensitive)





# **GENERAL INFORMATION**

#### **EXHIBITION**

Please be sure to visit the exhibits located in the Mezzanine (2nd Floor) at the breaks. View the Exhibitor Directory on page 58. All catering services will be located here. Exhibits open at 16.30 on Saturday, 14 May.

#### **POSTER SESSIONS**

Poster Session I: Sunday, 15 May

Room: Biscayne Ballroom (2nd Floor) Mandatory Stand by Time: 12.00-14.00

Poster Set Up: 17.30-19.00 on Saturday, 14 May Poster Dismantle: 10.00-10.30 on Monday, 16 May

Poster Session II: Tuesday, 17 May

Room: Biscayne Ballroom (2nd Floor) Mandatory Stand by Time: 12.00-14.00

Poster Set Up: 12.00-13.00 on Monday, 16 May Poster Dismantle: 14.00-15.00 on Tuesday, 17 May

#### **SOCIAL MEDIA**

Share your excitement about the PNS Annual Meeting using #PNS2022 on Twitter and Facebook.

#### ON-DEMAND PROGRAMMING

On-demand content will be available 5 business days after it has aired live (by 25 May). All plenary talks, education course talks, and sponsored symposia talks are being recorded for on-demand viewing.

#### **E-POSTER HALL**

The PNS e-poster hall will be available for viewing thru 31 December 2022.



# **ACKNOWLEDGEMENTS**

We thank the generosity of our sponsors and exhibitors. This meeting would not be possible without their support.

#### ANNUAL PARTNERS





# **GRIFOLS**







#### **SILVER SPONSORS**







# **ACKNOWLEDGEMENTS**

#### **BRONZE SPONSORS**









#### **EXHIBITORS**







### PATIENT ADVOCACY GROUPS (PAGS)



















# INDUSTRY-SPONSORED SYMPOSIA

We invite you to join each of our Annual Partners for their industry-sponsored symposium.

#### **SUNDAY, 15 MAY**



CSL Behring Symposium: Use of Immunoglobulin in the Individualized Management of CIDP

19.15-20.15 TRIANON BALLROOM (2ND FLOOR)



**IONIS Symposium: Mixed Phenotype ATTR Amyloidosis:** 

#### **MONDAY, 16 MAY**



Alnylam Symposium: Understanding, Diagnosing, and Treating the Polyneuropathy of hATTR Amyloidosis

6.45-7.45 CHOPIN BALLROOM (2ND FLOOR)



**Grifols Symposium: Immunoglobulins in CIDP:** Mechanisms of Action and New Genetic Insights

6.45-7.45 GRAND BALLROOM (2ND FLOOR)



Pfizer Symposium: An Intravenous Immunoglobulin Treatment With 2 FDA-Approved Maintenance Dosing Options for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

19.15-20.15 TRIANON BALLROOM (2ND FLOOR)



Takeda Symposium: A Practical Approach to Diagnosis and Management of MMN: Past, Present and Future

19.15-20.15 VERSAILLES BALLROOM (2ND FLOOR)



# IN-CONJUNCTION-WITH MEETINGS

CATURE	
SATURDA	AY, 14 MAY 2022
08.00-12.00	Inherited Neuropathy Meeting SANDRINGHAM/WINDSOR (2ND FLOOR) This is a closed meeting.
09.00-10.15	IGOS Meeting RAPHAEL/MICHELANGELO (2ND FLOOR) This is a closed meeting.
12.30-13.30	IMAGiNe Study Consortium Q&A Session RAPHAEL/MICHELANGELO (2ND FLOOR) This is a closed meeting.
13.40-15.10	CMTR Workgroup Meeting SANDRINGHAM/WINDSOR (2ND FLOOR)  All are welcome.
MONDAY	7, 16 MAY 2022
08.30-9.30	Patient Advocacy Group (PAG) Meeting BALMORAL (2ND FLOOR) This is a closed meeting.
10.00-10.30	IGOS Biobank Meeting BALMORAL (2ND FLOOR) This is an open meeting.
15.30-16.00	JPNS Editorial Board Meeting BALMORAL (2ND FLOOR) This is a closed meeting.
20.15-21.15	International Diabetes Neuropathy Consortium (IDNC) Board Meeting BALMORAL (2ND FLOOR) This is a closed meeting.
TUESDAY	7, 17 MAY 2022
10.00-10.30	Toxic Neuropathy Consortium (TNC) Board Meeting BALMORAL (2ND FLOOR) This is a closed meeting.
16.00-16.30	PNS Prize Committee Meeting GROVE (1ST FLOOR) This is a closed meeting.
16.00-16.30	PNS Annual Partner Roundtable Meeting BALMORAL (2ND FLOOR) This is a closed meeting.
17.30-18.30	Neuropathic Pain Consortium (NPC) Board Meeting BALMORAL (2ND FLOOR) This is a closed meeting.
WEDNES	DAY, 18 MAY 2022
07.30-08.30	Charcot-Marie-Tooth & Related Neuropathies (CMTR) Board Meeting ESCORIAL (2ND FLOOR) This is a closed meeting.
07.30-08.30	Inflammatory Neuropathy Consortium INC) Board Meeting RAPHAEL/MICHELANGELO (2ND FLOOR) This is a closed meeting.
09.00-12.00	Peripheral Nerve Society Board Meeting RAPHAEL/MICHELANGELO (2ND FLOOR) This is a closed meeting.





## PROGRAM – SATURDAY, 14 MAY 2022

8.00-10.20 Coffee & Registration MEZZANINE

8.00-12.00 Inherited Neuropathy Meeting SANDRINGHAM/WINDSOR ROOM

This is a closed meeting.

9.00-10.15 **IGOS Meeting** MICHAELANGELO/RAPHAEL ROOM

This is a closed meeting.

10.20-18.30 Education Course (All Are Welcome) Versailles Ballroom

Chairs: Kathryn Moss, PhD, Johns Hopkins University, Baltimore, MD, USA and Luuk Wieske, MD, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands

10.20



Microphysiological Models of Peripheral Nerve Michael J. Moore, PhD Tulane University/AxoSim, New Orleans, LA, USA

11.00





Electromyography: From the Clinic to the Lab Paola Alberti, MD, PhD University of Milano-Bicocca, Monza, Italy, and David Cornblath, MD Johns Hopkins University, Baltimore, MD, USA

Basics of Nerve Conduction/

11.40



Diagnosing and Misdiagnosing CIDP: Pitfalls and Red Flags Jeffrey Allen, MD University of Minnesota, Minneapolis, MN, USA



## PROGRAM – SATURDAY, 14 MAY 2022

12.20-13.50 Lunch Grand Ballroom Foyer

12.30-13.30 IMAGiNe Study Consortium Q&A Session RAPHAEL/MICHELANGELO

This is a closed meeting.

12.30-13.40 Career Development Lunch TRIANON BALLROOM

Pre-Registration Required

Hosted by the PNS Junior Committee, this event aims to provide junior investigators with an opportunity to discuss funding opportunities, career paths, and more in a small group setting with experts in the peripheral nerve field. Lunch will be provided.

13.40-15.10 CMTR Workgroup Meeting SANDRINGHAM/WINDSOR

All are welcome.

13.50-16.30 Education Course continued Versailles Ballroom

Chairs: Paola Alberti, MD, PhD, University of Milano-Bicocca, Monza, Italy, and Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

13.50



Mechanisms and Consequences of De- vs. Dysmelination Jun Li, MD, PhD Wayne State University, Detroit, MI, USA

14.30



Hallmarks of Non-CMT Inherited Neuropathies Vera Fridman, MD University of Colorado, Englewood, CO, USA

15.10



Neuroinflammation: Mechanisms Leading to Axonal Damage and Neuropathic Pain in Chemotherapy-induced Peripheral Toxicity Guido Cavaletti, MD University of Milano-Bicocca, Monza, Italy



## PROGRAM – SATURDAY, 14 MAY 2022

15.50



Pure Neural Leprosy Wilson Marques Junior, MD, PhD Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

16.30-17.00 Coffee Break & Exhibits MEZZANINE

17.00-18.30 Education Course Keynote Symposium: Nodes of Ranvier: From Assembly to Nodo-Paranodopathies (three-part talk) VERSAILLES BALLROOM

Chairs: Divyanshu Dubey, MD, Mayo Clinic, Rochester, MN, USA, and Marcus Pinto, MD, MS, Mayo Clinic, Rochester, MN, USA

17.00



Nodes, Paranodes and Juxtaparanodes: Normal Anatomy and Physiology Kleopas Kleopa, MD, FAAN The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

17.25



Immunology of the Node of Ranvier
Luis Querol, MD, PhD
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

17.50



Nodo-Paranodopathies: Clinical Phenotypes and Treatment Antonino Uncini, MD University "G. D'Annunzio" Chieti-Pescara, Italy, Monsampolo del Tronto, Italia

18.15 General Discussion (Q&A)



# PROGRAM - SATURDAY, 14 MAY 2022

#### 19.00-22.00 Junior & Welcome Reception Perez ART MUSEUM MIAMI (PAMM)



Help us honor our Junior and New Members of the Society by joining us at the Perez Art Museum Miami. The first hour (19.00-20.00) of this Junior and Welcome Reception is reserved only for Junior Members and New Members. All conference delegates are invited to attend starting at 20.00 (don't miss the special champagne toast and welcome from the PNS President!).

Heavy appetizers, drinks, and live entertainment will be provided.

The PNS has reserved the entire museum for PNS meeting attendees to walk and explore. The Perez Art Museum will be debuting its newest exhibit: *Marisol and Warhol Take New York*. PNS members will have one hour (20.00-21.00) of exclusive access to the museum exhibits, including *Marisol and Warhol Take New York*. The PNS has arranged for museum docents to be available.

The PAMM is conveniently located approximately 1 mile from the InterContinental Miami (transportation will be provided).

Perez Art Museum Miami Address: 1103 Biscayne Blvd, Miami, FL 33132

#### Timing:

19.00-20.00: Reserved for Junior & New Members Only

20.05-21.00: Exhibits Open for PNS Members to View: *Marisol and Warhol Take New York* (Docents Available) & Reception

21.00-22.00: Reception Continues/DJ



 6.30-7.45 Coffee Break & Exhibits MEZZANINE
 6.30-7.45 Poster Viewing BISCAYNE BALLROOM
 7.45-8.00 Presidential Welcome GRAND BALLROOM Richard Lewis, MD, Cedars-Sinai, Los Angeles, CA, USA

8.00-8.30 **Peter J. Dyck Plenary Lecture:** 

Diabetic Neuropathy: Light at the End of the Funnel? GRAND BALLROOM



Nigel Calcutt, PhD University of California San Diego, San Diego, CA, USA

Chairs:
Mirlinda Ademi, MD
University of Cambridge, Cambridge, United Kingdom, and
Brian Callaghan, MD, MS
University of Michigan, Ann Arbor, MI, USA

8.30-9.30 Platform Session I GRAND BALLROOM

Chairs: Mirlinda Ademi, MD, University of Cambridge, Cambridge, United Kingdom, and Brian Callaghan, MD, MS, University of Michigan, Ann Arbor, MI, USA

- 8.30 The Effect of Surgical Weight Loss on Neuropathy in the Severely Obese Evan Reynolds, PhD, University of Michigan, Ann Arbor, MI, USA
- 8.45 Comparison Of Three State of the Art Small Fibre Measures in Type 2
  Diabetic Polyneuropathy

Troels Jensen, MD, PhD, Aarhus University, Aarhus, Denmark

- 9.00 Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy Krish Chandrasekaran, PhD, University of Maryland School of Medicine, Baltimore, MD, USA
- 9.15 Metformin and Resistance Exercise Alleviate Stress-Induced Peripheral Injury in Type 2 Diabetes
  Lynn Ala'eddine, MSc/PhD Candidate, American University of Beirut,
  Beirut, Lebanon

9.30-10.00 Oral Poster Session I GRAND BALLROOM

Chairs: Brian Callaghan, MD, MS, University of Michigan, Ann Arbor, MI, USA, and Mirlinda Ademi, MD, University of Cambridge, Cambridge, United Kingdom

9.30 Sirtuin1 Mediated Deacetylation of E3 Ubiquitin Ligase NEDD4-1
Regulates Axonal Growth and Treats Diabetic Peripheral Neuropathy
Krish Chandrasekaran, PhD, University of Maryland School of Medicine,
Baltimore, MD, USA



	9.35	Effect of a Ketogenic Diet  Jonathan Enders, University of Kansas Medical Center, Kansas City, MO, USA
	9.40	Vagal Afferent Free Fatty Acid Receptor 3 (FFAR3) Regulates Feeding Behavior Tyler Cook, BS, Loyola University Chicago, Maywood, IL, USA
	9.45	Activation of 20-HETE Synthase Triggers Oxidative Injury and Peripheral Nerve Damage in Type 2 Diabetic Mice Assaad A. Eid, Prof., American University of Beirut, Beirut, Lebanon
	9.50	Structural Alterations Reduce Nociception in Mice Carrying the L799P-Gain-of-Function Variant in NaV1.9 Sodium Channel Annika Schmidt, Institute of Human Genetics, Aachen, Germany
	9.55	Pharmacological Inhibition of GCN2 is Efficacious in Mouse Models of CMT2D Robert Burgess, PhD, The Jackson Laboratory, Bar Harbor, ME, USA
10.00-10.30	Coffee B	reak & Exhibits mezzanine

# 10.30-11.00 Richard & Mary Bunge Plenary Lecture: Molecular Mechanisms Controlling PNS Myelin Formation and Maintenance GRAND BALLROOM



Carla Taveggia, PhD
San Raffaele Hospital, Milan, Italy

Chairs: Elisabetta Babetto, PhD SUNY at Buffalo, Buffalo, NY, USA, and Laura Feltri, MD SUNY at Buffalo, Buffalo, NY, USA

11.00-11.45 Platform Session II GRAND BALLROOM

Chairs: Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA, and Laura Feltri, MD, SUNY at Buffalo, Buffalo, NY, USA

- 11.00 Post-Onset Gene Therapy Improves Myelination in a CMT4C Model Kleopas Kleopa, MD, FAAN, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
- 11.15 Clinical and Pathophysiological Characterization of Anti-Pan-Neurofascin Associated Nodo-Paranodopathy

**Luise Appeltshauser, MD, Msc,** Universitätsklinikum Würzburg, Wuerzburg, Germany

11.30 Gli1 Regulates the Postnatal Acquisition of Peripheral Nerve Architecture Brendan Zotter, PhD, New York University School of Medicine, New York, NY, USA



11.45-12.00	Chairs: E	Oster Session II GRAND BALLROOM Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA, and Eltri, MD, SUNY at Buffalo, Buffalo, NY, USA
	11.45	Schwann Cell LRP1 is Essential for Conserving Myelin and Mitochondrial Integrity in Aged Peripheral Nerves Melissa Heredia, MS, University of California San Diego, La Jolla, CA, USA
	11.50	Mitochondrial Dysfunction is a Feature Of Paclitaxel and Oxaliplatin-Promoted Chemotherapy-Induced Peripheral Neurotoxicity Silvia Giatti, PhD, Università degli studi di Milano, Milano, Italy
	11.55	Human iPSC-Derived Organoid Model Recapitulates Rescuable Key Pathology Features of CMT1A Jonas Van lent, University of Antwerp, Antwerp, Belgium
12.00-14.00	Lunch &	Exhibits MEZZANINE
12.00-14.00	Poster S	ession   BISCAYNE BALLROOM
13.00-13.30	Guided Poster Hall Tour: Antibodies & Immunity VERSAILLES BALLROOM Chairs: Luise Appeltshauser, MD, Msc, Universitätsklinikum Würzburg, Wuerzburg, Germany, and Luis Querol, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain	
	13.00	Autoantibody Studies in the CIDP01/CIDP04 Clinical Trials Cinta Lleixà, Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
	13.04	Autoantibody Screening in Neuralgic Amyotrophy Patients Lorena Martín-Aguilar, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
	13.08	A Diagnostic Score for the Diagnosis of Anti-MAG Neuropathy or CIDP in Patients with High Titers of Anti-MAG Antibodies Pietro Doneddu, MD, IRCCS Humanitas Research Hospital, Milano, Italy
	13.12	In Vitro Anti-Glycolipid Antibody Production by Guillain-Barré Syndrome Patients' Derived B Cells Ruth Huizinga, PhD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
	13.16	Acute Relapsing Ataxic Sensory Neuronopathy with anti-FGFR3 Autoantibodies Mimicking Acute Myelopathy Julian Theuriet, Hospices Civils de Lyon, Lyon, France
	13.20	General Discussion (Q&A)



	13.00-13.30	TRIANON B Chairs: C	Poster Hall Tour: Diagnostics & Imaging in Neuropathies ALLROOM Chiara Briani, MD, University of Padova, Padova, Italy and Stephan Goedee, UMC Utrecht, Utrecht, Netherland
		13.00	Electrodiagnostic Subtyping in Guillain-Barré Syndrome: Application of Criteria by Neuromuscular Specialists in Current Clinical Practice Samuel Arends, Leidschendam, Netherlands
		13.04	Serum Peripherin is Superior to NFL as a Biomarker for Axonal Damage in Inflammatory Peripheral Nerve Disease Ryan Keh, MRCP, MBBCHIR, MRC Centre for Neuromuscular Diseases, London, United Kingdom
		13.08	The Effects of Implementing the EAN/PNS Guideline (Second Revision) on Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy Iris van Doorn, MD, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands
		13.12	Magnetic Resonance Neurography and Diffusion Tensor Imaging of the Sciatic Nerve in Hereditary Transthyretin Amyloidosis Polyneuropathy Alessandro Salvalaggio, MD, Department of Neuroscience, University of Padova, Padova, Italy
		13.16	A Cross-Sectional Analysis of Spinal MRI Findings in UK hATTR Luke O'Donnell, MB, BCh, BAO, University College London, London, United Kingdom
		13.20	General Discussion (Q&A)
	14.00-19.00	SPECIAL	INTEREST GROUP (SIG) CONCURRENT SESSIONS – INC & NPC

14.00

14.00-19.00



The Role of Complement in Immune-Mediated Neuropathies Peter J Spaeth, PhD Institute of Pharmacology, University of Berne, Berne, Switzerland

Chair: Luis Querol, MD, PhD Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

INFLAMMATORY NEUROPATHY CONSORTIUM (INC) VERSAILLES BALLROOM



14.45



Biomarkers of Disease Activity in Immune-Mediated Neuropathies
Jeffrey Allen, MD

University of Minnesota, Minneapolis, MN, USA

Chair: Ruth Huizinga, PhD Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

- 15.30 Coffee Break & Exhibits MEZZANINE
- 16.00 Oral Poster Presentations

Chairs: Karissa Gable, MD, Duke University, Durham, NC, USA, and Richard Lewis, MD, Cedars-Sinai, Los Angeles, CA, USA

- 16.00 Pathophysiological Effects of Anti-Neurofascin155 IgG3 and IgG4 In Vivo
  Katharina Hecker, Neurology, University Hospital Würzburg, Würzburg, Germany
- Neuropathies Amidst the Pandemic: Remote Assessment of Patient Needs and Phenotype Validation
  Maike Dohrn, MD, Hussman Institute for Human Genomics and Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Neurology, Medical Faculty of the RWTH Aachen University Hospital, Aachen, Germany
- 16.10 Proteomics Based Discovery of Biomarkers For Disease Activity In CIDP

**Luuk Wieske, MD, PhD,** Amsterdam University Medical Centers, Amsterdam, Netherlands

- 16.15 Autoantibody Screening in Idiopathic Small-Fiber Neuropathy Elba Pascual-Goñi, MD PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 16.20 Skin Biopsy Parameter-Driven Phenotyping of Autoimmune Neuropathies

**Young Gi Min, MD,** Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

- 16.25 Diagnostic Value of Standardized Nerve Ultrasound of the Plexus Brachialis in Chronic Inflammatory Neuropathies Nicolas Dubuisson, Woluwe St-Lambert, Belgium
- 16.30 IVIg-Exposure and Thromboembolic Event Risk: Findings from the UK Biobank

**Mahima Kapoor, MBBS, FRACP,** Alfred Hospital, Monash University Prahran, Victoria, Australia



16.35	Gut Microbiota as a Therapeutic Target to Ameliorate Neural Injury in Autoimmune Neuropathy Gang Zhang, PhD, The University of Texas Health Science Center at Houston, Houston, TX, USA
16.40	CSF IL-8 in Acute and Chronic Inflammatory Polyneuropathies Ivan Kmezic, Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden
16.45	Single Nucleotide Polymorphisms in Cytokine Genes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy Ivo Bozovic, Belgrade, Serbia
16.50	<b>Update on the Dutch Guillain-Barré syndrome Mimics Study</b> <b>Linda Luijten, MD,</b> <i>Erasmus MC University Medical Center</i> <i>Rotterdam, Rotterdam, Netherlands</i>
16.55	Early Recognition of Guillain-Barré Syndrome with Treatment-Related Fluctuations and Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy Linda Luijten, MD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
INC Proje	ct Updates
17.00	Chair Welcome Chiara Briani, MD, University of Padova, Padova, Italy
17.05	Update on IMAGiNe Study: The IgM M-protein Associated Neuropathy International Registry Tatiana Hamadeh, PhD, Maastricht University Medical Centre, Maastricht, Netherlands
17.10	Update on INCbase Filip Eftimov, MD, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands
17.15	Update on IGOS Bart Jacobs, MD, Erasmus MC, Rotterdam, Netherlands
17.20	Italian CIDP and MMN Databases and Rituximab Trials: Where We Are Eduardo Nobile-Orazio, MD, PhD, IRCCS Humanitas Research Hospital, Rozzano, Milan University, Italy, and Pietro Doneddu, MD, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
17.25	Grant Opportunities Available through the GBS   CIDP Foundation Lisa Butler, Executive Director, GBS   CIDP Foundation International, Conshohocken, PA, USA



17.00

17.30



Autoimmune Autonomic Neuropathies Valeria Iodice, MD, PhD Autonomic Unit, University College London, London, United Kingdom

Chair: Robert Hadden, MA, BM BCh, FRCP, PhD King's College Hospital, London, United Kingdom

18.15



Autoantibodies Associated with Paraneoplastic Neuropathies: Growing Spectrum and Relevance Divyanshu Dubey, MD

Mayo Clinic, Rochester, MN, USA

Chair: Christopher Klein, MD Mayo Clinic, Rochester, MN, USA

#### 14.00-19.00 NEUROPATHIC PAIN CONSORTIUM (NPC) TRIANON BALLROOM

14.00



Physiologic and Transcriptomic Findings in Human Dorsal Root Ganglia

Patrick Dougherty, PhD
The University of Texas M.D. Anderson Cancer Center, Pearland,
TX, USA

Chairs:

Theodore Price, PhD
University of Texas at Dallas, Dallas, TX, USA, and
Grace Shin, PhD
Zuckerman Mind Brain Behavior Institute, Columbia University,
New York, NY, USA

14.30 Platform Presentations

Chairs: Theodore Price, PhD, University of Texas at Dallas, Dallas, TX, USA, and Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

14.30 Real Time Imaging of Mitochondrial Dynamics in the Dorsal Root Ganglion Following Nerve Injury
Juliet Mwirigi, BS, Richardson, TX, USA

14.40 Microtubule Acetylation Rescues Capsaicin-Induced Neurite
Degeneration and May Predict Fiber Regeneration
Daniele Cartelli, PhD, Neuroalgology Unit, Fondazione IRCCS
Istituto Neurologico Carlo Besta, Milano, Italy



14.50 Neuron-Keratinocyte Communication in the Epidermis in Painful Diabetic Neuropathy

Dale George, PhD, Northwestern University, Chicago, IL, USA

15.00



Cannabinoids, Cannabis, and Cannabis-Based Medicines for Neuropathic Pain Management Andrew Rice, MD, FRCP, FRCA Imperial College, London, United Kingdom

Chairs:

James Russell, MD, MS

CAMC Institute for Academic Medicine, Charleston, WV, USA, and Stefano Tamburin, MD, PhD

University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy

15.30 Coffee Break & Exhibits MEZZANINE

16.00



Skin in the Game: Keratinocytes Communicate with Sensory Neurons to Convey Pain Cheryl Stucky, PhD Medical College of Wisconsin, Franklin, WI, USA

Chairs:

Daniele Cazzato, MD, PhD

IRCCS Foundation "C. Besta" Neurological Institute, Milan, Italy, and

Daniela Maria Menichella, MD, PhD

Northwestern University, Chicago, IL, USA

16.30 Oral Poster Presentations

Chairs: Daniele Cazzato, MD, PhD, IRCCS Foundation "C. Besta" Neurological Institute, Milan, Italy, and Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

16.30 Comparison of Amyloid Detection in the Skin and Tenosynovium of Transthyretin Amyloidosis Patients Amrita Daniel, MBBS, D Ortho, Johns Hopkins School of Medicine, Baltimore, MD, USA

16.35 Evaluation of Sex-Related Differences in Oxaliplatin-Induced Changes in the Expression of Endocannabinoid Receptors and Enzymes in Lumbar Ganglia
Maria Coronel, PhD, IIMT CONICET - Austral Pilar, Buenos Aires, Argentina

16.40 Sensory Quantification Suggests Partially Conserved Neural Substrates for Hind Limb Pain Associated with Distinct Etiologies

**LaTasha Crawford, VMD, PhD,** University of Wisconsin-Madison, Madison, WI, USA



16.45 Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv PN) in NEURO-TTRansform, a Phase 3 Study of Eplontersen Marcia Waddington Cruz, MD, National Amyloidosis Referral Center-CEPARM, University Hospital, Federal University of Rio de Janei, Rio de Janeiro, Brazil

16.50 A Mouse Strain with Decreased Scarring Abilities Demonstrates
Superior Peripheral Nerve Healing
David Milek, University of Rochester, Rochester, NY, USA

16.55 LXR Synthetic Agonist GW3965 Modifies Neuronal Lipid Homeostasis and Decreases Prostaglandin Production in the Dorsal Root Ganglia of Obese Mice

Nadia Elshareif, MS, Loyola University Chicago, Maywood, IL, USA

17.00



Skin Biopsy in the Clinic Claudia Sommer, MD

Department of Neurology, University Hosptial Würzburg, Würzburg, Germany

Chairs:

Giuseppe Lauria, MD

IRCCS Fondazione Istituto Neurologico Carlo Besta & University of Milan, Milano, Italy and

Stephanie Shiers, PhD

The University of Texas at Dallas, Dallas, TX, USA

#### 17.30 Platform Presentations

**Chairs:** Giuseppe Lauria, MD, IRCCS Fondazione Istituto Neurologico Carlo Besta & University of Milan, Milano, Italy and Stephanie Shiers, PhD, The University of Texas at Dallas, Dallas, TX, USA

- 17.30 Lack of Skin Cell-Secreted Neurotrophic Factors Results in a Small Fiber Neuropathy
  Paula Diaz Cespedes, PhD Candidate, Pontificia Universidad Católica de Chile, Santiago, Chile
- 17.40 Neurovascular Interactions in Skin Regeneration: From a Compartmentalized Model to a 3D Tissue-Engineered Skin Amandine Rovini, PhD, INSERM U1026, Université de Limoges, Limoges, France
- 17.50 Dysregulated MicroRNA Profile in Skin Epidermis Contributes to Small Fiber Pathophysiology
  Mirna Andelic, PhD Candidate, Fondazione IRCCS Istituto
  Neurologico "Carlo Besta" Milano, Italy



18.00



**Sensory Neurons Modulate Skin Inflammation** Dan Kaplan, MD, PhD University of Pittsburgh, PA, USA

Chairs: Patrik Ernfors, PhD Karolinska Institutet, Solna, Sweden, and Cheryl Stucky, PhD Medical College of Wisconsin, Franklin, WI, USA

18.30 Panel Discussion with all Speakers

> Chairs: Dale George, PhD, Postdoc Fellow, Northwestern University, Chicago, IL, USA, and Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

19.00-19.15 Break MEZZANINE 19.15-20.15 Sponsored Symposia

#### CSL Behring Biotherapies for Life™

#### CSL Behring Symposium: Use of Immunoglobulin in the Individualized Management of CIDP TRIANON BALLROOM

19.15 Welcome and Introductions Amanda Peltier, MD, MS, Vanderbilt University Medical Center, Nashville, TN, USA 19.20 Mechanisms of Action of Intravenous Immunoglobulin in CIDP Marinos Dalakas, MD, Thomas Jefferson University, Philadelphia, PA, USA 19.35 Will the New 2021 EAN/PNS Guideline Improve CIDP Diagnosis Accuracy? Mazen Dimachkie, MD, University of Kansas Medical Center, Kansas City, KS, USA 19.50 Treatment of CIDP: How Far Have We Gone? **Jeffrey Allen, MD,** University of Minnesota, Minneapolis, MN, USA 20.05 Q&A Amanda Peltier, MD, MS, Vanderbilt University Medical Center, Nashville, TN, USA 20.10 Close Amanda Peltier, MD, MS, Vanderbilt University Medical Center, Nashville, TN, USA



# IONIS Sponsored Symposium: Mixed Phenotype ATTR Amyloidosis: Are We Seeing the Whole Patient? VERSAILLES BALLROOM

19.15 Introduction Sami L. Khella, MD, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

19.20 Neurologist's Perspective: ATTR Pathophysiology, Diagnosis, and Management

P. James B. Dyck, MD, Mayo Clinic, Rochester, MN, USA



19.40 Cardiologist's Perspective: ATTR Pathophysiology, Diagnosis,

and Management

Jose Nativi-Nicolau, MD, Mayo Clinic, Jacksonville, FL, USA

20.00 Summary and Q&A

Sami L. Khella, MD, University of Pennsylvania School of Medicine,

Philadelphia, PA, USA

6.45-8.00 Coffee & Exhibits MEZZANINE

6.45-7.45 Sponsored Symposia



#### Alnylam Alnylam Sponsored Symposium: Understanding, Diagnosing, and Treating the Polyneuropathy of hATTR Amyloidosis CHOPIN BALLROOM

Welcome and Introductions

Moderator: George Beran, Alnylam Pharmaceuticals, Cambridge, MA

Overview of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis Amanda Peltier, MD, Vanderbilt University Medical Center, Nashville, TN

Review of a Hypothetical Patient Case with the Polyneuropathy of hATTR Amyloidosis

Amanda Peltier, MD, Vanderbilt University Medical Center, Nashville, TN, and Alejandra González-Duarte, MD, NYU Langone Health, New York, NY

Overview of a Treatment for the Polyneuropathy of hATTR Amyloidosis Alejandra González-Duarte, MD, NYU Langone Health, New York, NY

Q&A

Moderator: George Beran, Alnylam Pharmaceuticals, Cambridge, MA Alejandra González-Duarte, MD, NYU Langone Health, New York, NY, and Amanda Peltier, MD, Vanderbilt University Medical Center, Nashville, TN

**GRIFOLS** Grifols Sponsored Symposium: Immunoglobulins in CIDP: Mechanisms of Action and New Genetic Insights grand BALLROOM Chair: Norman Latov, MD, PhD, Weill Cornell Medical College, New York, NY, USA

- 6.45 Introduction. Program and SPIN Award 2022 Ceremony Norman Latov, MD, PhD, Weill Cornell Medical College, New York, NY, USA
- 6.55 Mechanisms of Action of Immunoglobulin in CIDP Marinos Dalakas, MD, FAAN, Thomas Jefferson University, Philadelphia, PA, USA
- 7.15 Genetic Variations and Clinical Factors Affecting the Response to Immunoglobulin in CIDP Krista Kuitwaard, MD, PhD, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
- 7.35 Q&A and Wrap Up Norman Latov, MD, PhD, Weill Cornell Medical College, New York, NY, USA and Faculty



# 8.00-8.30 Anita Harding Plenary Lecture: The Role of Blood Neural Barriers in Motor Nerve Degeneration GRAND BALLROOM



Charlotte Sumner, MD

Johns Hopkins University School of Medicine, Baltimore, MD, USA

#### Chairs: Maike Dohrn, MD

Hussman Institute for Human Genomics and Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Neurology, Medical Faculty of the RWTH Aachen University Hospital, Aachen, Germany, and

Mary Reilly, MD, FRCP, FRCPI, FMedSci University College London, London, United Kingdom

#### 8.30-9.30 Platform Session III GRAND BALLROOM

Chairs: Maike Dohrn, MD, Hussman Institute for Human Genomics and Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Neurology, Medical Faculty of the RWTH Aachen University Hospital, Aachen, Germany, and Mary Reilly, MD, FRCP, FRCPI, FMedSci, University College London, London, United Kingdom

- 8.30 PMP22 Overexpression Causes Lipid Recycling Defects that Alters the Plasma Membrane In CMT1A
  - Robert Prior, PhD Candidate, VIB/KU Leuven, Leuven, Belgium
- 8.45 COVID-19 Vaccination and Guillain-Barré Syndrome: Analyses using the National Immunoglobulin Database

**Ryan Keh, MRCP, MBBCHIR,** MRC Centre for Neuromuscular Diseases, London, United Kingdom

- 9.00 Complement Inhibition Prevents Paranodal Loop Injury in an Anti-GM1
  Antibody-Mediated Paranodal Demyelinating Mouse Model
  Clare Campbell, BSc, University of Glasgow, Glasgow, United Kingdom
- 9.15 Myelinated Human Sensory Neurons Provide a Platform for the Reproducible Screening of Peripheral Nerve-Reactive Autoantibodies in Patient Sera
- Alexander Davies, PhD, University of Oxford, Oxford, United Kingdom

### 8.30-9.30 Patient Advocacy Group (PAG) Meeting BALMORAL

This is a closed meeting.



9.30-10.00	Oral Poster Session III GRAND BALLROOM  Chairs: Maike Dohrn, MD, Hussman Institute for Human Genomics and Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Neurology, Medical Faculty of the RWTH Aachen University Hospital, Aachen, Germany, and Mary Reilly, MD, FRCP, FRCPI, FMedSci, University College London, London, United Kingdom	
	9.30	Targeting Muscle to Rescue Impaired Axonal Transport in Charcot-Marie- Tooth Disease James Sleigh, DPhil, UCL Institute of Neurology, London, United Kingdom
	9.35	Activation of the UPR Transcription Factors XBP1 and ATF6 Modulates Disease Severity in CMT1B Mice Maurizio D'Antonio, PhD, San Raffaele Scientific Institute, Milan, Italy
	9.40	WITHDRAWN
	9.45	Normal Aging of the Peripheral Nervous System in the General Population: Clinical and Electrophysiological Characteristics Noor Taams, MD, Erasmus University Medical Center, Rotterdam, Netherlands
	9.50	Zebrafish In Vivo Imaging of Innate Immune Cell Interactions with Cutaneous Axons in a Paclitaxel Neurotoxicity Model Antonio Cadiz Diaz, PhD, University of Miami Coral Gables, FL, USA
	9.55	Kinome Dysregulation in a CMT2E iPSC-Derived Motor Neuron System Jessica Medina, Graduate Student, University of Miami Miller School of Medicine Miami, FL, USA
10.00-10.30	Coffee Break & Exhibits MEZZANINE	
10.00-10.30	IGOS Biobank Meeting BALMORAL This is an open meeting.	

10.30-11.00 Jack Griffin Plenary Lecture: The Schwann Cell-Associated Secretory Phenotype as a Therapeutic Target for Nerve Repair GRAND BALLROOM



Felipe A. Court, PhD
Center for Integrative Biology, Universidad Mayor, Santiago, Chile

Chairs:
Marcus Pinto, MD, MS
Mayo Clinic, Rochester, MN, USA, and
John Svaren, PhD
University of Wisconsin-Madison, Madison, WI, USA

11.00-11.45	Platform Session IV GRAND BALLROOM Chairs: Marcus Pinto, MD, MS, Mayo Clinic, Rochester, MN, USA, and John Svaren, PhD, University of Wisconsin-Madison, Madison, WI, USA		
	11.00	Programming Injury-Induced Enhancers in Schwann Cells Raghu Ramesh, University of Wisconsin-Madison, Madison, WI, USA	
	11.15	PACSIN1-Binding to LRP1, a Pro Survival Receptor in Schwann Cells, Transactivates TrkC via a SRC Family Kinase-Dependent Pathway Stefano Martellucci, PhD, University of California San Diego, San Diego, CA, USA	
	11.30	Discovery of Pain-Associated Neuroimmune Protein Interaction Networks from Sex Differential Neuronal and Immune Gene Expression Profiles in Human DRGs Pradipta Ray, PhD, UT Dallas, Dallas, TX, USA	
11.45-12.00	Oral Poster Session IV GRAND BALLROOM Chairs: Marcus Pinto, MD, MS, Mayo Clinic, Rochester, MN, USA, and John Svaren, PhD, University of Wisconsin-Madison, Madison, WI, USA		
	11.45	A C. Elegans Model of Neuropathy-Associated GARS1 Mutations Jennifer Pierluissi, University of Michigan, Ann Arbor, MI, USA	
	11.50	Imaging Calcium Changes in Ex Vivo Mouse Models of Axonal Guillain-Barré Syndrome Madeleine Cunningham, PhD, University of Glasgow, Glasgow, United Kingdom	
	11.55	WITHDRAWN	
12.00-12.30	All are er	nnual General Meeting (All Are Welcome) GRAND BALLROOM accouraged to attend the PNS Annual General Meeting as we highlight exciting ety initiatives. Your input is valuable as we review the business of the PNS.	
12.30-14.00 Lunch & Exhibits MEZZANINE		Exhibits mezzanine	



13.00-13.30	Guided Poster Hall Tour: COVID/Vaccine Neuropathy VERSAILLES BALLROOM Chairs: Michael Lunn, PhD, National Hospital for Neurology and Neurosurgery Queen Square, London, United Kingdom, and Antonino Uncini, MD, University "G. D'Annunzio" Chieti-Pescara, Italy, Monsampolo del Tronto, Italia	
	13.00	Various Peripheral Nerve Complications Associated with COVID-19 Vaccination: A Case Study David Lauer, MD, Department of Neurology, Third Faculty of Medicine, Charles University, UH Kralovske Vinohrady, Prague, Czech Republic
	13.04	An Inflammatory Lumbar Radiculoplexopathy Pos Severe COVID-19 Infection Associated with Heterotopic Ossification Camila Pupe, PhD, Universidade Federal Fluminense, Rio de Janeiro/RJ, Brazil
	13.08	Is This An Acute Autonomic Neuropathy Related To COVID Vaccine? João Marcus de Lima Brito Alves, MD, Universide of São Paulo, Ribeirao Preto, Brazil
	13.12	Peripheral Neuropathy Evaluations of Patients with Long-COVID Anne Oaklander, MD, PhD, Massachusetts General Hosp, Boston, MA, USA
	13.16	Risk of Recurrences of Guillain-Barré Syndrome or Exacerbations of CIDP and MMN After SARS-CoV-2 Vaccination Adaja Baars, MD, Erasmus Medical Center, Rotterdam, Netherlands
	13.20	General Discussion (Q&A)
13.00-13.30	Chairs: B	Poster Hall Tour: Stem Cells TRIANON BALLROOM ruce Conklin, MD, Gladstone Institutes, UCSF, San Francisco, CA, USA, and porta, MD, PhD, MBA, University of Miami Miller School of Medicine, USA
	13.00	Pre-Clinical Studies in Induced Pluripotent Stem Cell (iPSC) Lines with SORD Mutations Linked to a Recessive Neuropathy Christopher Yanick, Miami, FL, USA
	13.04	Molecular Characterization of Human Dorsal Root Ganglion Using Spatial RNA Sequencing and RNAscope in Situ Hybridization Stephanie Shiers, PhD, The University of Texas at Dallas, Richardson, TX, USA
	13.08	IPSC-Derived Motor Neurons Reveal Progressive Mitochondrial Dysfunction in Axonal CMT Subtypes Jonas Van lent, University of Antwerp, Antwerp, Belgium
	13.12	A hiPS-Derived Cellular Model of Motor Neurons to Investigate Impaired Mechanisms in GDAP1-Associated Charcot-Marie-Tooth Disease Federica Miressi, PhD, University of Limoges, Limoges, Haute-Vienne, France
	13.16	Severe Congenital Myasthenic Syndromes Caused by AGRIN Mutations Affecting Secretion by Motoneurons Arnaud Jacquier, PhD, NeuroMyoGene Institut, Lyon, France
	13.20	General Discussion (Q&A)



14.00-19.00 SPECIAL INTEREST GROUP (SIG) CONCURRENT SESSIONS – CMTR, IDNC & TNC

14.00-19.00 CHARCOT-MARIE-TOOTH & RELATED
NEUROPATHIES CONSORTIUM (CMTR) VERSAILLES BALLROOM

14.00



An Update on Treating ATTR Amyloidosis Isabel Conceição, MD CHULN-Hospital de Santa Maria, Faculty of Medicine, Lisbon, Portugal

Chairs:
Matilde Laurá, MD, PhD
University College London Hospital, London, United Kingdom, and
Pedro Tomaselli, MD, MSc, PhD
Clinical Hospital of Ribeirão Preto, University of São Paulo, São Paulo,
Brazil

14.30 Platform Presentations

Chairs: Matilde Laurá, MD, PhD, University College London Hospital, London, United Kingdom, and Pedro Tomaselli, MD, MSc, PhD, Clinical Hospital of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

14.30 Skin Amyloid Deposits and Nerve Fiber Loss as Markers of Neuropathy Onset and Progression in Hereditary Transthyretin Amyloidosis
Luca Leonardi, Ospedale Sant'Andrea Roma, Roma, Italy

14.45 Plasma and Skin Biomarkers for Charcot-Marie Tooth Disease John Svaren, PhD, University of Wisconsin-Madison, Madison, WI, USA

15.00



The Genetics of Pain-Related Neuropathies
Ingo Kurth, MD
Institute of Human Genetics, Medical Faculty, RWTH Aachen
University, Aachen, Germany

Chairs:
Jonathan Baets, MD, PhD
Antwerp University Hospital, Antwerp, Belgium, and
Andrea Cortese, MD, PhD
Queen Square Centre for Neuromuscular Diseases, London,
United Kingdom

15.30 Coffee Break & Exhibits MEZZANINE



16.00 Platform Presentations

Chairs: Jonathan Baets, MD, PhD, Antwerp University Hospital, Antwerp, Belgium, and Andrea Cortese, MD, PhD, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom

16.00 A Recurrent Missense Variant in ITPR3 is Associated with Demyelinating CMT

Danique Beijer, PhD, University of Miami, Miami, FL, USA

Danique Deijer, Frib, Oniversity of Wilami, Wilami, Ft., 03A

16.15 Repeat Expansion Size Predicts Age of Onset in RFC1 CANVAS and Disease Spectrum

**Riccardo Currò, MD,** Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

16.30



Mechanistic Understanding and Therapeutic Discovery for Peripheral Neuropathy using Drosophila Models Grace Zhai, PhD

University of Miami Miller School of Medicine, Miami, FL, USA

Chairs:

Shawna Feely, MS, LGC University of Iowa Health Care, Iowa City, IA, USA, and Mario Saporta, MD, PhD, MBA University of Miami, Miami, FL, USA

17.00 Platform Presentations

Chairs: Shawna Feely, MS, LGC, University of Iowa Health Care, Iowa City, IA, USA, and Mario Saporta, MD, PhD, MBA, University of Miami, Miami, FL, USA

17.00 Using Machine Learning to Prioritize Rare Repeat Expansions for Pathogenicity

Sarah Fazal, MSc, University of Miami, Miami, FL, USA

17.15 The Role of ATF4 Target-Gene Expression on Neuropathy
Phenotype in Mouse Models of Charcot-Marie-Tooth Disease
Type 2D

Timothy Hines, PhD, The Jackson Laboratory, Bar Harbor, ME, USA

17.30



Outcome Measures and Niomarkers in CMT for Successful Trial Readiness

David Herrmann, MBBCh

University of Rochester, Rochester, NY, USA

Chairs:

Alexia Kagiava, PhD, MSc

The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, and Michael Shy, MD

University of Iowa, Iowa City, IA, USA



18.00 Platform Presentations

Chairs: Alexia Kagiava, PhD, MSc, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, and Michael Shy, MD, University of Iowa, Iowa City, IA, USA

18.00 MAVERICK: Variant Prioritization for Mendelian Diseases Using Deep Learning
Matt Danzi, PhD, University of Miami, Miami, FL, USA

18.15 Long-Term Effects of AAV9-MicroRNA-Mediated Gene Silencing in a CMT1A Mouse Model
Marina Stavrou, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

18.30 Late-Breaking Abstracts

Chairs: Vera Fridman, MD, University of Colorado, Englewood, CO, USA, and Marina Kennerson, PhD, ANZAC Research Institute, Conford, Australia

18.30 Aldose Reductase Inhibitor AT-007 Prevents Mitochondrial Dysfunction And Neurodegeneration in Sorbitol Dehydrogenase Deficiency-Induced Neuropathy Yi Zhu, MD, PhD, University of Miami, Miami, FL, USA

18.45 Structural Variation and Gene-Intergenic Fusions: A Novel Mechanism of Neurodegeneration in Motor Neuron Diseases Anthony Cutrupi, PhD, Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia

14.00-19.00 INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM (IDNC)

CHOPIN BALLROOM

14.00 Welcome James Russell, MD, MS, CAMC Institute for Academic Medicine, Charleston, WV, USA

14.05



Programmed Axon Death and Human Disease: Pathogenic and Therapeutic Implications in Diabetic Neuropathy

Michael Coleman, PhD
University of Cambridge, Cambridge, United Kingdom

Chair:
James Russell, MD, MS
CAMC Institute for Academic Medicine, Charleston, WV, USA



14.50 Platform Presentations
Chair: James Russell, MD, MS, CAMC Institute for Academic Medicine,
Charleston, WV, USA

14.50 Plasma Neurofilament Light Chain Concentrations are Elevated in Youth-Onset T2D and Associate with Diabetic Neuropathy Vera Fridman, MD, University of Colorado, Englewood, CO, USA

15.00 Prevalence and Risk Factor Profiles for Chronic Axonal Polyneuropathy in the General Population Noor Taams, MD, Erasmus University Medical Center, Rotterdam, Netherlands

15.10 Interactions Between Human Peripheral Sensory Neurons and Immune Cells
Diana Tavares Ferreira, PhD, Plano, TX, USA

15.20 Dietary Interventions in DB/DB Mice Improve Metabolic and Kidney Profiles, but not Peripheral Neuropathy Stephanie Eid, PhD, University of Michigan, Ann Arbor, MI, USA

15.30 Coffee Break & Exhibits MEZZANINE

16.00



Vera Fridman, MD
University of Colorado, Englewood, CO, USA

Chair: Rodica Pop-Busui, MD, PhD University of Michigan, Ann Arbor, MI, USA

16.45



Neuroimmune Regulation of Remission and Relapse of Neuropathic Pain

**Geoffroy Laumet, PhD,** Michigan State University, East Lansing, MI, USA

Chair:

**Douglas Wright, PhD,** University of Kansas Medical Center, Kansas City, KS, USA



17.30



Inflammation as a Therapeutic Target for Diabetic Peripheral Neuropathy

Rodica Pop-Busui, MD, PhD University of Michigan, Ann Arbor, MI, USA

**Chair: Christopher Gibbons, MD, MMSc** *Harvard Medical School, Boston, MA, USA* 

18.15 Oral Poster Presentations

Chair: Douglas Wright, PhD, University of Kansas Medical Center, Kansas City, KS, USA

- 18.15 Determining the Prevalence of Distal Symmetric Polyneuropathy in a Low-Income U.S. Patient Population Melissa Elafros, MD, PhD, University of Michigan, Ann Arbor, MI, USA
- 18.20 Submicron Topographic Cues Enhance Directionality of Peripheral Nerve Regenerating Fibers
  Michele Fornaro, Midwestern University, Downers Grove, IL, USA
- 18.25 How Often is Peripheral Neuropathy Diagnosed in Patients Referred to an Academic Neuromuscular Clinic?
  Benn Smith, MD, Mayo Clinic, Scottsdale, AZ, USA
- 18.30 Diabetic Lumbosacral Radiculoplexus Neuropathy after COVID-19
  Marcus Pinto, MD, MS, Mayo Clinic Rochester, MN, USA
- 18.35 Ice-Induced Epidermal Denervation: a New Model To Study Degeneration and Regeneration of Skin Nerves
  Daniele Cazzato, MD, PhD, IRCCS Foundation "C. Besta"
  Neurological Institute, Milan, Italy
- 18.40 The Unmet Need for Disease Modification in Diabetic Peripheral Neuropathy. First Steps: The Taxonomy Project
  Roy Freeman, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
- 18.55 Closing Remarks

**James Russell, MD, MS,** CAMC Institute for Academic Medicine, Charleston, WV, USA



#### 14.00-19.00 TOXIC NEUROPATHY CONSORTIUM (TNC) TRIANON BALLROOM


14.00



Emerging Mechanisms of Nerve Damage in CIPN Nathan Staff, MD, PhD Mayo Clinic, Rochester, MN, USA

Chair: Sandra Rieger, PhD University of Miami, Coral Gables, FL, USA

14.30



15.10



Different Approaches to CIPN Assessment: Serum Biomarkers Paola Alberti, MD, PhD University of Milano-Bicocca, Monza, Italy

Discussant: Communication Comm

**General Discussion** 

Apps and Wearables for Remote CIPN Monitoring Nathan Daniel Hertz, PharmD, PhD University of Michigan, Ann Arbor, MI, USA

Chair:
Chiara Briani, MD
University of Padova, Padova, Italy

15.30	Coffee Break & Exhibits MEZZANINE
16.00	Update on TNC Activities Guido Cavaletti, MD, University of Milano-Bicocca, Milan, Italy
16.30	Platform Presentations Chair: Andreas Argyriou, MD, PhD, Saint Andrew's State General Hospital of Patras; Neurology Dept., Patras, Greece

- 16.30 Neuron-Macrophage Interactions in Models of Chemotherapy-Induced Peripheral Neuropathy
  Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute,
  Columbia University, New York, NY, USA
- 16.45 Characterization of Axonal Degeneration Mechanisms in Bortezomib-Treated Sensory Neurons
  Laura Monza, PhD, Experimental Neurology Unit, School of Medicine and Surgery, Monza, Italy



	17.00	Netazepide is Neuroprotective in a Mouse Model of Vincristine- Induced Sensory Neuropathy Amandine Bernard, PhD Student, EA6309, Limoges, France
	17.15	Neuroprotective Effect of hlg in Mouse Models of Chemotherapy-Induced Neuropathy Aurore Danigo, PhD, EA6309_MMNP, Faculté de Médecine et de Pharmacie Limoges, Cedex, France
	17.30	Morpho-Functional Characterization of the Caudal Nerve to Refine Assessment of Peripheral Neuropathy in Rat Models Paola Alberti, MD, PhD, University of Milano-Bicocca, Monza, Italy
	17.45	Functional Characterisation of Missense Variants in the Pro-Survival Gene NMNAT2 Mirlinda Ademi, MD, University of Cambridge, Cambridge, United Kingdom
	18.00	Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neuropathy Fawaz Mahfouz, BAdvSc (Hons), The University of Sydney, Camperdown, Australia
	18.15	Bortezomib Neuropathy: Characteristics of a Cohort from a Tertiary Multiple Myeloma Treatment Center Daniel Schirmer, cand. med., Universitätsklinikum Würzburg, Würzburg, Germany
	18.30	A Study of Endemic Sensory, Optic and Auditory Neuropathy in the UK Black Caribbean Community Caroline Kramarz, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, United Kingdom
	18.45	Information and Communication Technology Devices and Applications for Chemotherapy-Induced Peripheral Neurotoxicity: a Systematic Review Stefano Tamburin, MD, PhD, University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy
•		



This is a closed meeting.

19.00-19.15 Break MEZZANINE

19.15-20.15 Sponsored Symposia





Pfizer Sponsored Symposium: An Intravenous Immunoglobulin Treatment With 2 FDA-Approved Maintenance Dosing Options for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

TRIANON BALLROOM

**Speaker:** Sami Khella, MD, Professor of Clinical Neurology, University of Pennsylvania School of Medicine, and Chief, Department of Neurology, Penn Presbyterian Medical Center, Pennsylvania, PA, USA



# Takeda Sponsored Symposium: A Practical Approach to Diagnosis and Management of MMN: Past, Present and Future VERSAILLES BALLROOM

19.15	Welcome, Introductions and Objectives Jeffrey Allen, MD, University of Minnesota, Minneapolis, MN, USA
19.18	What is MMN? Disease Overview and Pathophysiology Norman Latov, MD, PhD, Weill Cornell Medicine, New York, NY, USA
19.33	What is the Future for Diagnosing MMN? Overcoming Challenges in Current Diagnostic Approaches for MMN Mamantha Pasnoor, MD, The University of Kansas Medical Center, Kansas City, KS, USA
19.48	What are the Unmet Needs for Patients with MMN? Following the Patient Journey Jeffrey Allen, MD, University of Minnesota, Minneapolis, MN, USA
20.03	Q&A Session All Faculty
20.15	Meeting Close

20.15-21.15 International Diabetes Neuropathy Consortium (IDNC) Board Meeting BALMORAL This is a closed meeting.



6.45-8.00 Coffee & Exhibits MEZZANINE

6.45-8.00 Poster Viewing BISCAYNE BALLROOM

8.00-8.30 PK Thomas Plenary Lecture: Gene Therapies for Inherited Demyelinating Neuropathies GRAND BALLROOM



Kleopas Kleopa, MD, FAAN

The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

Chairs:

Kathryn Moss, PhD

Johns Hopkins University, Baltimore, MD, USA, and

Steven Scherer, MD, PhD

The University of Pennsylvania, Media, PA, USA

8.30-9.30 Platform Session V GRAND BALLROOM

Chairs: Kathryn Moss, PhD, Johns Hopkins University, Baltimore, MD, USA, and Steven Scherer, MD, PhD, The University of Pennsylvania, Media, PA, USA

8.30 Preclinical Evaluation of CLZ-2002, Neuronal Regeneration Promoting

Cells in a CMT IA Mouse Model

**Sung-Chul Jung, Professor,** Ewha Womans University College of Medicine, Seoul, Republic of Korea

, 1

8.45 Clustering Peripheral Neuropathy Models with Transcriptomic Data to

Identify Shared Pathways, Predictive Signatures, and Therapeutic Targets
George Murray, The Jackson Laboratory / The University of Maine,

Bar Harbor, ME, USA

9.00 Development of ORT247, a Monoclonal Antibody Antagonist of EphA4,

for the Treatment of CMT and ALS

Michael Ahlijanian, PhD, Orthogonal Neuroscience, Newton Centre,

MA, USA

9.15 A Role for Calpain in Secondary Loss of Axonal Integrity in Experimental

**Models of Paranodal Demyelination** 

Rhona McGonigal, PhD, University of Glasgow, Glasgow, United Kingdom

9.30-10.00 Oral Poster Session V GRAND BALLROOM

Chairs: Kathryn Moss, PhD, Johns Hopkins University, Baltimore, MD, USA, and Steven Scherer, MD, PhD, The University of Pennsylvania, Media, PA, USA

9.30 Allele-Specific Inactivation of Dominant CMT2E Mutations via CRISPR

**Targeting Common Polymorphisms** 

Luke Judge, MD, PhD, Gladstone Institutes, San Francisco, CA, USA



	9.35	The First Two Large Deletions of KIF5A Responsible for Charcot-Marie- Tooth Disease, Detected Using CovCopCan Software Ioanna Pyromali, Université de Limoges, Limoges, France
	9.40	Biallelic Variants in COQ7 Leading to Coenzyme Q10 Deficiency Cause Charcot-Marie-Tooth Disease Adriana Rebelo, PhD, University of Miami, Miami, FL, USA
	9.45	Neurodegeneration in HSAN1 due to ATL1 (Gly66Gln) Mutation is Associated with Defective ER- Protein Quality Control and Compromised Autophagy Istvan Katona, MD, RWTH Aachen University, Insitute of Neuropathology, Aachen, Germany
	9.50	Update on the International Guillain-Barré syndrome Outcome Study (IGOS) Robin Thomma, MD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
	9.55	A Model For Therapeutic Screening Of Chemotherapy-Induced Peripheral Neuropathy Using A Nerve-on-a-Chip Microphysiological System J. Curley, PhD, AxoSim, Inc., New Orleans, LA, USA
10.00-10.30	Coffee Br	eak & Exhibits MEZZANINE
10.00-10.30	TNC Board Meeting BALMORAL (2ND FLOOR) This is a closed meeting.	

10.30-11.00 Jonathan Pembroke Plenary Lecture: Transduction of Light Touch and Mechanical Pain by Sensory Schwann Cells GRAND BALLROOM



Patrik Ernfors, PhD Karolinska Institutet, Solna, Sweden

Chairs:
Daniela Maria Menichella, MD, PhD
Northwestern University, Chicago, IL, USA, and
Grace Shin, PhD
Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

11.00-11.45 Platform Session VI GRAND BALLROOM

Chairs: Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA, and Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

11.00 Targeting the Sigma 2 Receptor/TMEM97 to Treat Neuropathic Pain Muhammad Saad Yousuf, PhD, University of Texas at Dallas, Richardson, TX, USA



	11.15	Activation of Keratinocyte Gq-linked G-Protein Coupled Receptors Remodels Dorsal Root Ganglion Neurons Single-Cell Transcriptomic Profile Abdelhak Belmadani, PhD, Northwestern University Feinberg School of Medicine, Chicago, IL, USA	
	11.30	Persistence of Intact Sensory Afferents and Myelin Thinning Correlates with Long-Term Hypersensitivity after Partial Crush of the Peripheral Nerve Alexander Davies, PhD, University of Oxford, Oxford, United Kingdom	
11.45-12.00	Chairs: Dand Grac	ester Session VI GRAND BALLROOM Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA, se Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, K, NY, USA	
	11.45	Changes in the Expression of TRP Channels Induced by Oxaliplatin in Lumbar Dorsal Root Ganglia and Spinal Cord of Male and Female Rats Constanza Miguel, PhD Candidate, Instituto de Investigaciones en Medicina Traslacional-Conicet-Universidad Austral, Pilar, Argentina	
	11.50	TRPA1 Rare Variants in Chronic Neuropathic Pain Patients Margherita Marchi, MSc, IRCCS Istituto Neurologico C. Besta, Milano, Italy	
	11.55	Nerve Regeneration Following Ablation of Monocarboxylate Transporters 1, 2 and 4 from Schwann Cells Joseph Passero, John Hopkins University School of Medicine, Baltimore, MD, USA	
12.00-14.00	Lunch & Exhibits MEZZANINE		
12.00-14.00	Poster Session II BISCAYNE BALLROOM		
13.00-13.30	Guided Poster Hall Tour: Fluid Biomarkers VERSAILLES BALLROOM Chairs: Krista Kuitwaard, MD, PhD, Erasmus MC, Rotterdam, Netherlands, and Alexander Rossor, FRCP, PhD, UCL, London, United Kingdom		
	13.00	Serum Neurofilament Light Chain Associated with Outcome in Guillain- Barré Syndrome Across Regional and Disease Spectrums Henk-Andre Kroon, MD, MBA, Annexon Biosciences, Brisbane, CA, USA	
	13.04	Longitudinal Serum Neurofilament Light Chain Levels as Biomarker of Axonal Injury in Guillain-Barré Syndrome Sander van Tilburg, Drs, Erasmus MC, Rotterdam, Netherlands	
	13.08	Biomarkers Associated with Disease Severity and Outcome in Guillain-Barré Syndrome: a Prospective Cohort Study Israt Jahan, MS, Laboratory of Gut-Brain Signaling, Laboratory Sciences and Services Division, icddr,b, Dhaka, Bangladesh	



	13.12	NCAM1 and GDF15 are Biomarkers of Charcot-Marie-Tooth Disease in Patients and Mice Matthew Jennings, PhD, Cambridge University, Cambridge, United Kingdom
	13.16	Utility of Plasma Neurofilament Light Chain in Determining Subclinical Disease Activity in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Mahima Kapoor, MBBS, FRACP, Alfred Hospital, Monash University Prahran, Victoria, Australia
	13.20	General Discussion (Q&A)
13.00-13.30	Chairs: Te	Poster Hall Tour: Trials & Therapies TRIANON BALLROOM Presa Coelho, MD, Hospital de Santo Antonio, Porto, Portugal, and nov, MD, PhD, University of Amsterdam, Amsterdam, Netherlands
	13.00	AT-007 Significantly Lowers Blood Sorbitol Levels in Patients with Hereditary Neuropathy Resulting from Sorbitol Dehydrogenase (SORD) Deficiency Riccardo Perfetti, MD, PhD, Applied Therapeutics, New York, NY, USA
	13.04	Allografts in Combination with Local Immune Suppression as a Strategy to Improve Peripheral Nerve Regeneration JuliAnne Allgood, University of Wyoming, Laramie, WY, USA
	13.08	Assessment Timing and Choice of Outcome Measure in Determining Treatment Response in CIDP: a Post-Hoc Analysis of the PRISM Trial Rabye Ouaja, Dr, LFB, Les Ulis, France
	13.12	Population Pharmacokinetic Modeling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome Sander van Tilburg, Drs, Erasmus MC, Rotterdam, Netherlands
	13.16	Real-World Experience with Inotersen at Ceparm University Hospital Marcia Cruz, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
	13.20	General Discussion (Q&A)
14.00-16.00	Basic Sc	ience Highlights versailles ballroom
14.00-14.40	Chair: Ru	th Huizinga, PhD, Erasmus MC University Medical Center Rotterdam, n, Netherlands
	14.00	Introduction Ruth Huizinga, PhD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
	14.06	Neuron-Macrophage Interactions in Models of Chemotherapy-Induced Peripheral Neuropathy Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA



14.12	Interactions Between Human Peripheral Sensory Neurons and Immune Cells Diana Tavares Ferreira, PhD, Plano, TX, USA		
14.18	Discovery of Pain-Associated Neuroimmune Protein Interaction Networks from Sex Differential Neuronal and Immune Gene Expression Profiles in Human DRGs Pradipta Ray, PhD, UT Dallas, Dallas, TX, USA		
14.24	Downregulation of Leukocyte LKB1/AMPK Signaling is Associated with the Severity of Guillain-Barre Syndrome Independently of Autophagy Ivo Bozovic, Belgrade, Serbia		
14.30	Q&A with all Speakers Ruth Huizinga, PhD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands		
	njury Responses in Neurons and Glia isabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA		
14.40	Introduction Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA		
14.45	Injury, Degeneration, and Regeneration Speakers: Courtney Hatton, The Jackson Laboratory, Old Town, ME, USA Stefano Martellucci, PhD, University of California San Diego, San Diego, CA, USA Juliet Mwirigi, BS, Richardson, TX, USA Joseph Passero, John Hopkins University School of Medicine, Baltimore, MD, USA Raghu Ramesh, University of Wisconsin-Madison, Madison, WI, USA		
14.55	Cell-Cell Interaction in Injury and Disease Speakers: Melissa Heredia, MS, University of California San Diego, La Jolla, CA, USA James Sleigh, DPhil, UCL Institute of Neurology, London, United Kingdom		
15.05	Q&A with all Speakers		



14.40-15.20

Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA

15.20-16.00	Part III: Peripheral Mechanisms of Neuropathic Pain Chair: Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA		
	15.20	Introduction Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA	
	15.30	Panel Discussion Speakers: Paula Diaz Cespedes, PhD(c), Pontificia Universidad Católica de Chile, Santiago, Chile Patrik Ernfors, PhD, Karolinska Institutet, Solna, Sweden Dale George, PhD, Postdoc Fellow, Northwestern University, Chicago, IL, USA	
	15.50	<b>Q&amp;A with all Speakers Grace Shin, PhD,</b> Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA	
14.00-16.00	Chairs: N	A.C. Hughes Symposium: Clinical Highlights TRIANON BALLROOM Mary Reilly, MD, FRCP, FRCPI, FMedSci, University College London, London, ingdom, and David Cornblath, MD, Johns Hopkins University, Baltimore,	
	14.00	Natural History Study of Sord Neuropathy Andrea Cortese, MD, PhD, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom	
	14.10	MRI Measured Dixon Fat Fraction is a Responsive Outcome Measure in CMT1X, CMT1B, and CMT2A Carolynne Doherty, MD, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom	
	14.20	Predictors of Mobility, Balance, and Lower Extremity Function in Adult Charcot-Marie-Tooth Disease Type 1 Timothy Estilow, OT, The Children's Hospital of Philadelphia & University of Philadelphia, Philadelphia, PA, USA	
	14.30	Neuropathy Progression in ATTRv Patients after Orthotopic Liver Transplant Catarina Falcao de Campos, Hospital Santa Marta, Lisbon, Portugal	
	14.40	WITHDRAWN	
	14.50	HELIOS-A: Impact of Vutrisiran on Quality of Life and Functional Status in Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy Senda Ajroud-Driss, MD, Northwestern University, Chicago, IL, USA	



	15.00	Peripheral Neuropathy (CSPN): a NeuroNEXT Trial Gordon Smith, MD, VCU, Richmond, Virginia, USA	
	15.10	A Double-Blind, Placebo Controlled Trial of IVIG in Patient with Small Fiber Neuropathy Associated with Autoantibodies to TS-HDS and FGFR3 Christopher Gibbons, MD, MMSc, Harvard Medical School, Boston, MA, USA	
	15.20	Rozanolixizumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Randomized Subject-/Investigator-Blind Placebo-Controlled Phase 2a Trial Luis Querol, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain	
	15.30	OPTIC Trial: Intravenous Immunoglobin and Intravenous Methylprednisolone as Induction Treatment in CIDP – Study Update Iris van Doorn, MD, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands	
	15.40	Italian Database on Multifocal Motor Neuropathy: Lesson from the First 100 Included Patients Eduardo Nobile-Orazio, MD, PhD, Milan University, IRCCS Humanitas Research Institute Rozzano, Milan, Lombardia, Italy	
	15.50	Target Therapies: Towards a Tailored Therapy in Anti-MAG Antibody Neuropathy with Ibrutinib, Venetoclax, and Obinutuzumab Francesca Castellani, MD, Department of Neurosciences, Neurology Padova, Padova, Italy	
16.00-16.30	Coffee B	Break & Exhibits MEZZANINE	
16.00-16.30		PNS Prize Committee Meeting GROVE (1ST FLOOR) This is a closed meeting.	
16.00-16.30		nual Partners Roundtable Meeting BALMORAL closed meeting.	
16.30-17.00	Arthur K. Asbury/Presidential Plenary Lecture: Improve the Lives of		





Pieter van Doorn, MD, PhD Erasmus MC University Medical Center, Rotterdam, Netherlands

Chairs: Rich Lewis, MD Cedars-Sinai, Los Angeles, CA, USA, and Luuk Wieske, MD, PhD Amsterdam University Medical Centers, Amsterdam, Netherlands



17.00-17.30 Awards Ceremony GRAND BALLROOM

Master of Ceremonies: Rich Lewis, MD, Cedars-Sinai, Los Angeles, CA, USA Please join us as we honor one of our esteemed PNS colleagues with the presentation of the prestigious Alan J. Gebhart Prize for Excellence in Peripheral Nerve Research. We will also present several \$750 cash prizes to Junior Member abstract presenters at the awards ceremony. Being chosen as a prize winner is considered an honor and commemorates the contributions of previous leaders in the industry.

17.30-18.30 **Neuropathic Pain Consortium (NPC) Board Meeting** BALMORAL This is a closed meeting.

19.00-22.00 Closing Reception Intercontinental MIAMI SKYLAWN - POOL DECK (5TH FLOOR)



Located on the 5th-floor pool deck, the hotel's SkyLawn overlooks the Miami skyline. Join us for a private reception with live music, dancing, and more. The PNS has reserved the entire rooftop area for the Closing Reception. Appetizers and drinks will be provided.

# PROGRAM – WEDNESDAY, 18 MAY 2022

07.30-08.30	Charcot-Marie-Tooth & Related Neuropathies (CMTR) Board Meeting
	ESCORIAL This is a closed meeting.


- 07.30-08.30 Inflammatory Neuropathy Consortium (INC) Board Meeting RAPHAEL/MICHELANGELO This is a closed meeting.
- 09.00-12.00 **Peripheral Nerve Society (PNS) Board Meeting** RAPHAEL/MICHELANGELO This is a closed meeting.





# **EXHIBITOR MAP**

# INTERCONTINENTAL HOTEL MEZZANINE LEVEL 2









#### Alnylam Pharmaceuticals Medical

#### BOOTH #1

BOOTH #2

www.alnylam.com medinfo@alnylam.com

About Alnylam Pharmaceuticals Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. For more information visit www.alnylam.com.





www.grifols.com/en/home immunologyneurology@grifols.com

Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions — Bioscience, Diagnostic, Hospital and Bio Supplies — develop, produce and market innovative medicines, solutions and services in more than 100 countries.





#### **IONIS**

#### BOOTH #3

www.ionispharma.com medinfo@ionisph.com

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. To learn more, visit www.ionispharma.com.





#### Janssen Pharmaceuticals

#### BOOTH #4

www.janssen.com www.twitter.com/JanssenGlobal

At Janssen, we're creating a future where disease is a thing of the past — including rare diseases, which affect 300 million people around the globe. That's why we're investigating new approaches to the treatment of rare neurological diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP). Follow us at www.twitter.com/JanssenGlobal for updates.







#### Sanofi BOOTH #5

www.sanofi.com/en/your-health/specialty-care med.info@sanofi.com

Sanofi's Specialty Care business is committed to meeting significant unmet medical needs. With a well-established heritage in multiple sclerosis, we continue to forge the way in neurology, seeking to provide hope where none existed before, developing innovative approaches to treatments based on patient insights, scientific expertise, and cutting-edge technology. By partnering with scientific, healthcare and patient communities, we continue to build on our legacy of collaboration and inspiration, understanding and experience, empathy and knowledge to drive the development of potential new therapies and to help change what it means to live with a neurological disease. Learn more about these partnerships and possibilities at https://www.sanofi.com/en/your-health/ specialty-care MAT-US-2100661





## **CSL Behring Medical Affairs**

BOOTH #6

www.cslbehring.com www.cslbehring.com/contact

CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.





#### Takeda - Commercial Booth

BOOTH #7

www.takeda.com US.corporatecommunications@takeda.com

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. www.takeda.com



#### **KabaFusion**

BOOTH #8

www.KabaFusion.com LSerpa@KabaFusion.com

KabaFusion is a patient-focused, pharmacist-owned, home infusion provider. We are dedicated to working proactively with our patients, healthcare practitioners and payors to provide comprehensive support before, during, and after treatment. KabaFusion has years of experience providing home infusions and is recognize for excellence in the administration of Intravenous Immune Globulin (IVIG) nationwide. If you would like to refer your next IVIG patient to KabaFusion, please contact us by phone or fill out our online IVIG referral form at: www.KabaFusion.com





#### **European CMT Federation**

BOOTH #9

www.ecmtf.org secretary@ecmtf.org

The European CMT Federation (ECMTF) is a non-profit organization grouping European national associations supporting people affected by the Charcot-Marie-Tooth disease. One of our primary goals is to encourage research projects for an affordable and effective treatment, and to raise awareness on CMT. We believe in cooperation. Together we are stronger.



# Muscular Dystrophy Association BOOTH # 10

www.mda.org ResourceCenter@mdausa.org

MDA is the largest source of funding for neuromuscular research outside of the federal government. We are working aggressively to advance therapy development through support of innovative research in universities and industry and through collection of healthcare data in the MOVR Data Hub. Since our inception in the 1950's we have invested over \$1B in R&D and 8 drugs have come to market partly through our sponsorship and support. We also maintain a network of over 150 care centers across the United States, providing care for 60,000 patients living with muscular dystrophy, ALS and other neuromuscular diseases annually, to give access to expert multidisciplinary care, clinical trials, and engage with MDA and the neuromuscular community.



#### **CMT Research Foundation**

BOOTH #11

www.cmtrf.org info@cmtrf.org

The mission of the CMT Research Foundation is to deliver treatments and cures for CMT during our lifetime. Founded by two patients who are driven to expedite drug delivery to people who live with CMT globally, the organization supports research focused on the discovery and development of therapeutics. The CMT Research Foundation pursues this goal by identifying and bridging gaps in biomedical research, with a focus on areas that are most likely to result in treatments. We are most focused on translational research, but also fund discovery phase research with a clear link to speeding progress toward treatments and cures. The CMT Research Foundation accepts proposals that address four key scientific barriers to drug development: delivering therapies to the peripheral nervous system, advancing genetic medicine, promoting nerve health, and de-risking clinical trials.





# Hunters CMT4B3 Research Foundation BOOTH #12

www.cmt4b3research.org info@cmt4b3research.org

Hunters CMT4B3 Research Foundation, was founded to fund, support and advance research including the development and production of therapeutic treatments for Charcot-Marie-Tooth Disease Type 4B3 (CMT4B3) and other related inherited neuromuscular disorders. The mission of the foundation is to improve public awareness of CMT, advance education, develop gene therapies, novel drug discovery and drug repurposing treatments, as well as implement a patient registry for CMT4B3 to improve the quality of life of those suffering from this disorder.



# Hereditary Neuropathy Foundation (HNF)

**BOOTH #13** 

www.hnf-cure.org info@hnf-cure.org

HNF held the monumental FDA El-PFDD meeting. HNF funds impactful research with dozens of academic/industry collaborations, including biotech seed funding. HNF is patient powered, patient centered and patient driven! HNFs Inspire® Support Community, the patient registry, GRIN, and the Al Powered CMT Mobile App are at the core mission.



# Charcot-Marie-Tooth Association (CMTA)

**BOOTH #14** 

www.cmtausa.org Info@cmtausa.org

Founded by patients in 1983, the vision of the CMTA has always been a "A World Without CMT" and we will accomplish this mission by accelerating research and empowering patients. We are devoted to: 1. Driving the development of new drugs to treat CMT 2. Meeting the needs of patients with CMT 3. Accelerating research for a cure Leading us in our mission is the governing CMTA Board of Directors and a STAR Advisory Board comprised of the world's foremost CMT research scientists, clinicians and experts in the field of developing pharmacological therapeutics. The CMTA has an incredible community of patients, families, and supportive friends — along with hundreds of experts in neurology, genetics, orthopedic surgery, physiatry, physical therapy and podiatry — all committed to our vision.



# GBS|CIDP Foundation International BOOTH #15

gbs-cidp.org info@gbs-cidp.org

The GBS/CIDP Foundation International is the preeminent global non-profit organization supporting individuals and their families affected by Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and related syndromes such as multifocal motor neuropathy (MMN) through a commitment to support, education, research and advocacy.





### The Foundation for **Peripheral Neuropathy**

**BOOTH #16** 

www.foundationforpn.org info@tffpn.org

The Foundation for Peripheral Neuropathy aims to improve the lives of patients living with PN. We do so by funding research grants, lobbying for more research dollars through the DOD and the NIH, raising awareness of PN, providing educational resources to patients, and funding the PN Research Registry, FPN's very own unique biobank of DNA samples from over 2,000 patients for researchers to access.



# ANNUAL

## Alnylam Pharmaceuticals

**BOOTH #17** 

www.alnylam.com info@alnylam.com

About Alnylam Pharmaceuticals Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. For more information visit www.alnylam.com.



#### **PHARNEXT**

**BOOTH #18** 

pharnext.com/en contact@pharnext.com

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A ('CMT1A') and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer's disease and will be advanced through partnerships.



# Octapharma AG

**BOOTH #19** 

www.octapharma.com

Octapharma is one of the world's largest human protein manufacturers, developing and producing human proteins from human plasma and human cell lines. We employ around 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology, and Critical Care.











#### **Applied Therapeutics**

BOOTH #20

www.appliedtherapeutics.com info@appliedtherapeutics.com

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, such as Sorbitol Dehydrogenase (SORD) Deficiency. When someone is living with a debilitating disease for which no drugs are available, everyday counts.





#### Takeda - Medical Booth

**BOOTH #22** 

www.takeda.com US.corporatecommunications@takeda.com

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. www.takeda.com





# Pfizer, Inc.

www.pfizer.com

About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.







## CSL Behring

**BOOTH #23** 

www.cslbehring.com/contact

CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.





#### Neurocode Lab

BOOTH #25

www.neurocode.com info@neurocode.com

A CAP/CLIA accredited clinical laboratory located in Bellingham Washington. Seeking excellence in neuroimmunology and neurodegeneration testing. As the first USA based clinical laboratory, offers best in class cell-based testing for CIDP and Myasthenia Gravis



#### Variantyx

**BOOTH #27** 

variantyx.com info@variantyx.com

Variantyx uses a unique whole genome platform to identify all major genetic changes from a single patient sample. The Genomic Unity® test portfolio has industry-leading sensitivity and specificity, with easy reflex options to comprehensive analyses. Together, we can rapidly end the diagnostic search, inform management, and optimize treatment.



#### argenx

BOOTH #26

www.argenx.com medinfo@argenx.com

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases by translating immunology breakthroughs into potential new medicines. argenx has offices in Belgium, the United States, Japan, and Geneva. Visit us at www.argenx.com. Follow us on LinkedIn and Twitter.





#### **AxoSim**

#### **BOOTH #28**

axosim.com info@axosim.com

AxoSim empowers advancements in human neuroscience by partnering with leading pharmaceutical and research institutions to facilitate therapeutic breakthroughs in the world's most devastating neurodegenerative diseases.

The NerveSim® platform is the only in vitro model with Schwann cell myelination and human-relevant electrophysiological and structural data metrics, unlocking a powerful tool for human translation.

The BrainSim® platform is being developed to upend the way drugs are screened for myelin-related diseases of the CNS, such as multiple sclerosis and leukodystrophies.

With innovative drug discovery tools, AxoSim offers clinically-relevant data to select better lead candidates with functional, phenotypically accurate assays. AxoSim enables its partners to move safe and effective candidates toward the clinic faster than it has been done before.





# Use of Immunoglobulin in the Individualized Management of CIDP



**Trianon Ballroom, InterContinental Miami** Sunday, May 15, 2022, 7:15–8:15 PM





**Dr Amanda Peltier**Vanderbilt University Medical Center **Chair** 



**Prof Marinos Dalakas** Thomas Jefferson University

Mechanisms of Action of Intravenous Immunoglobulin in CIDP



**Dr Jeffery Allen** University of Minnesota

Will the New 2021 EAN/PNS Guideline Improve CIDP Diagnosis Accuracy?



Prof Mazen Dimachkie
University of Kansas Medical Center
Treatment of CIDP: How Far Have We Gone?
Followed by Interactive
Audience Q&A session


# 2022 PNS ANNUAL MEETING

**IONIS-SPONSORED SYMPOSIUM** 

MIXED PHENOTYPE ATTR AMYLOIDOSIS:

# ARE WE SEEING THE WHOLE PATIENT?

Sunday, May 15, 2022 7:15 PM—8:15 PM | Versailles Ballroom, InterContinental Miami, Miami, Florida



#### **Moderator**



**Sami L. Khella, MD**University of Pennsylvania
School of Medicine
Philadelphia, PA

#### **Faculty**



**P. James B. Dyck, MD** Mayo Clinic, Rochester, MN



**Jose Nativi-Nicolau, MD** Mayo Clinic, Jacksonville, FL


Join Dr Sami L. Khella and our expert faculty for an in-depth discussion of the identification and management challenges of patients with mixed-phenotype ATTR amyloidosis.

Join Dr Sami Khella and our expert faculty for an in-depth discussion of the identification and management challenges of patients with ATTR-PN, ATTR-CM, and mixed-phenotype ATTR. Hear about the pathophysiology, diagnosis, and management of patients with ATTR amyloidosis from the neurologist's and cardiologist's perspectives. Faculty will also discuss the challenges of diagnosing ATTR amyloidosis with an emphasis on the benefits of a holistic and multidisciplinary approach to disease management.



# CARING FOR PEOPLE

Since its founding in 1909, Grifols has worked continuously to provide innovative medicines and solutions that improve the health and well-being of people around the world.






An Intravenous Immunoglobulin Treatment
With 2 FDA-Approved Maintenance Dosing
Options for Adults With Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)

Date: Monday, May 16, 2022

Time: 7:15 pm - 8:15 pm

**Location:** Trianon Ballroom



Presented by Dr Sami Khella, MD

Professor of Clinical Neurology, University of Pennsylvania School of Medicine, and Chief, Department of Neurology, Penn Presbyterian Medical Center

Visit our LIVE Pfizer Exhibit at Table #21

Or visit our Pfizer Ig Virtual Exhibit Booth at https://www.vr-exhibit.com/Pfizer/IG/2205



PP-PAN-USA-0405 © 2022 Pfizer Inc. All rights reserved. April 2022

# A Practical Approach to Diagnosis and Management of MMN: Past, Present and Future

May 16 2022, 7:15 – 8:15 pm, Versailles Ballroom

Join our experts in an interactive learning experience during which you will have the opportunity to learn about key challenges associated with multifocal motor neuropathy (MMN) and follow the patient journey.



**Dr Jeffrey Allen** (Chair) Associate Professor of Neurology University of Minnesota Minnesota, USA



**Dr Norman Latov**Professor of Neurology
Weill Cornell Medicine
New York City, USA



**Dr Mamatha Pasnoor**Professor of Neurology
University of Kansas Medical Center
Kansas, USA

TIME (EDT)	TOPIC	FORMAT	SPEAKER(S)
7:15 pm	Welcome, introductions and objectives	Plenary	Dr Jeffrey Allen
7:18 pm	What is MMN? Disease overview and pathophysiology	Plenary	Dr Norman Latov
7:33 pm	What is the future for diagnosing MMN?  Overcoming challenges in current diagnostic approaches for MMN	Plenary	Dr Mamatha Pasnoor
7:48 pm	What are the unmet needs for patients with MMN? Following the patient journey	Case-based discussion	Dr Jeffrey Allen
8:03 pm	Q&A session	Q&A	All Faculty
8:15 pm	Meeting Close		



# Join us at a Breakfast Symposium sponsored by Alnylam Pharmaceuticals during the Peripheral Nerve Society 2022 Annual Meeting!

#### **ABOUT THE PROGRAM\***

Join our distinguished presenters as they discuss recognizing, diagnosing, and managing adult patients with polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. The presenters will also review the clinical profile for a treatment for the polyneuropathy of hATTR amyloidosis in adults.

#### **SPEAKERS**

Alejandra González-Duarte, MD Associate Director and Associate Professor in the Department of Neurology NYU Langone Health New York, NY

Amanda Peltier, MD, MS
Chief of the Division of Neuromuscular Disorders,
Professor in the Department of Neurology and Medicine,
and Associate Vice Chair of Faculty Affairs
Vanderbilt University Medical Center
Nashville, TN

#### **PROGRAM DATE & TIME**

Monday, May 16, 2022 6:45 AM-7:45 AM ET


#### **PROGRAM LOCATION**

Intercontinental Miami, Chopin Ballroom, Mezzanine Level

This event does not qualify for continuing education credit.


\*Intended for US Healthcare Professionals only.





Visit www.pnsociety.com to learn more about these exclusive member benefits!





# Journal of the Peripheral Nervous System (JPNS)

Publishes original research reports, reviews, letters, and news covering every topic of scientific or clinical relevance to the peripheral nervous system.

Read, cite and submit your paper to *JPNS* 



#### Publish with JPNS and experience the benefits:



An expedient decision process and time to online publication, with article transfer option.



A reputable journal, with a diverse and global editorial team, adding value for 20+ years.



Global reach of researchers and practitioners at 13,000+ institutions.



Expanded research impact through optional video abstract submission to accompany your article.



# Publishing Open Access?

Your fees may be covered... check now: https://bit.ly/APCfunders



Read the latest JPNS Special Issue Images from the Nerve: An Atlas for Neurologists



**Did you know?** When compared to subscription articles, open access articles published by us receive, on average:

- 3.2X more downloads
- **1.5X** more cites
- **4.7X** higher Altmetric scores
- 2.7X higher Altmetric scores

